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ABSTRACT 
 
Background and objectives: Supraclavicular plexus block provides good alternative 
to General anaesthesia for upper limb surgeries with good postoperative analgesia. 
Various drugs have tried as adjuncts to local anaesthetics for brachial plexus block to 
enhance the quality and duration of analgesia. The present study was undertaken to 
assess the effect of Tramadol added to brachial plexus block by supraclavicular 
approach for onset and duration of block and postoperative analgesia. 
Methods: A prospective, randomized, double blinded study was conducted on 60 ASA 
I or II adult patients undergoing upper limb surgeries under supraclavicular brachial 
plexus block. Patients were randomly divided into two groups. Patients in Group B (n 
= 30) were administered 38mL of 0.25% Bupivacaine + 2ml Normal saline and Group 
BT (n = 30) were given 38mL of 0.25% Bupivacaine + 2ml Tramadol (2mg/kg). The 
onset time and duration of sensory and motor blockade were recorded. Haemodynamic 
variables (i.e., heart rate, systolic and diastolic blood pressure, oxygen saturation), and 
rescue analgesic requirements were recorded for 24 hrs postoperatively. 
Results: The onset of sensory and motor block was significantly faster in Group BT 
compared to Group B (P < 0.05). Rescue analgesic requirements were significantly 
less in Group BT compared to Group B (P < 0.05). Haemodynamic variables did not 
differ between groups in the post-operative period. 
Conclusion: Thus Tramadol (2mg/kg) in combination with 38mL of Bupivacaine 
(0.25%) was found to be good agent for hastening the onset of sensory and motor 
block and improved postoperative analgesia when used in brachial plexus block 
without producing any adverse events. 
Keywords: Supraclavicular brachial plexus block; Tramadol. 
3 
 
1.INTRODUCTION 
 
“Man uses his arms and hand constantly… as a result he 
exposes his arms and hands to injury constantly… Man also eats 
constantly… Man’s stomach is never really empty… The 
combination of man’s prehensibility and his unflagging appetite 
keeps a steady flow of patients with injured upper extremities and 
full stomachs streaming into hospital emergency rooms. This is why 
the brachial plexus is so frequently the anaesthesiologist’s favorite 
group of nerves” - Classical Anaesthesia Files, David little, 19631. 
 
Brachial plexus block is an alternative technique to general 
anaesthesia for upper limb surgeries. They produce complete 
muscular relaxation, maintaining stable intraoperative hemodynamic 
condition and sympathetic block which reduces postoperative pain. 
 
Brachial plexus block is used today to provide anaesthesia for 
upper limb surgeries. There are four usual sites of approach. 
1. Interscalene approach 
2. Supraclavicular approach 
a. Classic approach 
b. Plumb –bob technique 
c. Subclavian perivascular technique 
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3. Axillary approach 
4. Infraclavicular approach 
Among the four approaches, Supraclavicular brachial plexus 
block is a very popular mode of anaesthesia for various upper limb 
surgeries. This approach is attractive due to its effectiveness in terms 
of cost and performance, margin of safety, along with good 
postoperative analgesia. It also has the reputation of providing most 
complete and reliable anaesthesia for upper limb surgeries. The 
plexus is blocked at the level of trunk where it is most compact i.e. at 
the middle of brachial plexus, resulting in homogenous spread of 
anaesthetic throughout the plexus with a faster onset and complete 
block. 
 
Bupivacaine is one of the commonly used local anaesthetics as 
it has a longer duration of action varying from 3 to 8 hours. 
However, it has limiting factors like delayed onset, patchy or 
incomplete analgesia. To minimize these drawbacks many drugs like 
neostigmine, opioids, hyaluronidase, midazolam, clonidine
 
etc., have 
been added to local anaesthetics to improve the quality and duration 
of action and postoperative analgesia. 
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A variety of opioids have been studied for brachial plexus 
blockade including tramadolκ. Tramadol is a synthetic 4-phenyl-
piperidine analog of codeine has a unique mode of action. First, it 
stimulates the μ receptor and to lesser extent δ and κ-opioids 
receptors. Then by nonopioid mechanism it also activates spinal 
inhibition of pain by decreasing the reuptake of norepinephrine and 
serotonin from the nerve endings and potentiates the effect of local 
anaesthetics when mixed together in peripheral regional nerve block. 
It has less respiratory depressant effect due to weak µ receptor 
affinity. 
 
The present study is being undertaken to evaluate the onset 
time, duration and postoperative analgesic efficacy of bupivacaine 
and tramadol   for brachial plexus block by supraclavicular approach. 
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1. AIM OF THE STUDY 
 
To evaluate the effects of adding tramadol (2mg/kg)  as an 
adjuvant to bupivacaine (0.25%)  in brachial plexus block by 
supraclavicular approach with regard to the following parameters: 
 Onset time  and duration of sensory blockade 
 Onset time and duration of motor blockade  
 Duration of analgesia  
 Untoward side effects 
 Hemodynamic variables 
 Number of rescue analgesics in the postoperative 24hours 
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2. HISTORY 
 
HISTORICAL REVIEW 
“History, although sometimes made up of the few acts of the 
great, is more often shaped by the many acts of the small”  
- Mark Yost. 
1901- Harry Cushing’s first used the term Regional 
anaesthesia to describe pain relief by nerve block. The term regional 
analgesia denotes the interruption of pain impulses by physiological 
blockade at a certain point along their pathway of transmission in the 
peripheral nerves. 
 
HISTORY OF BRACHIAL PLEXUS BLOCK 
1. 1885 - William Stewart Halsted performed the first brachial 
plexus block.   
2. 1886 - Carl Koller demonstrated the anaesthetic properties of 
cocaine on the eye  of patient. 
3. 1897 - George Crile used a similar technique in which the 
plexus was exposed under local anaesthesia in a 12 year old 
boy. 
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EVOLUTION OF SUPRACLAVICULAR BRACHIAL 
PLEXUS BLOCK
2
 
1. 1911-1912 - Kulenkampff described the first percutaneous 
supraclavicular approach. He pointed out that above the 
clavicle the plexus lies under the skin as it passes over the first 
rib and accessible to a percutaneous technique.  
2. 1922- Labat G advocated an injection at three separate points 
which failed to elicit parasthesia by Kulenkampff’s method. 
First injection, beneath the deep fascia in the direction of the 
first rib, second towards the chassaignac’s tubercle and third 
towards the lateral margin of the first rib behind the clavicle (5 
ml with each injection). 
3. 1926 - Livingston carried out Kulenkampff’s technique 
without the production of parasthesia as soon as the deep 
cervical fascia had been penetrated. He wrote that the plexus 
and the artery are separated from the surrounding structures by 
a fascial investment. 
4. 1940 - Patrick chooses to lay down a “wall of anaesthetic” 
through which the plexus must pass in its course over the first 
rib, where 60-70 ml of solution was being injected during 5-6 
insertions. This technique became the “standard technique” of 
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supraclavicular block, subsequently referred to by many as the 
“classical supraclavicular technique”. 
5. 1942 - Knight modified Patrick’s technique by making the 
three injections through three separate needle insertions, 
parallel to one another. For the first time he directed the needle 
insertion caudally. 
6. 1944- Murphey used a single injection technique and used 
lateral border of anterior scalene muscle as the landmark and 
direction of needle insertion caudal as with Knight’s 
technique, not medial or dorsal, as with most other techniques. 
7. 1949 - Bonica and Moore utilized Kulenkampff’s and 
Patrick’s technique and developed a technique where it begins 
with utilizing the classical landmarks and direction of needle 
insertion and demands a definite parasthesia prior to first 
injection. Then continued as Patrick’s technique by laying 
down a wall of anaesthetic solution by “Walking the rib” and 
makes multiple injections during each withdrawal of the 
needle. This was used over the subsequent twenty years. 
8. 1958 - Lookman fully realized the potential of the fascial 
sheath, who like Livingston realised on the fascial investment 
of the plexus. He carefully dissected the plexus and said that 
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plexus lies in a closed compartment. He said this space lies 
between the anterior and middle scalene muscles and is 
pyramidal in shape, with its apex pointing upwards and 
medially towards the extent of the fourth cervical vertebra. He 
did not verify the needle’s proper placement within space 
before the injection. He admitted the tendency for the point of 
the needle to pass too posteriorly and hence to come to be 
within the substance of (or even behind) the middle scalene 
muscle. 
9. 1964 - Winnie after numerous anatomical dissections showed 
that the relation of the plexus and the subclavian artery to the 
midpoint of the first rib is not constant. He showed that there 
is a constant relationship between the anterior and middle 
scalene muscles, the plexus and the first rib. The plexus 
between the scalene muscles always insert on the first rib. He 
inserted needle between the two muscles in the direction of the 
space between them. Once a parasthesia is obtained, a single 
injection is made into the space.  
10. Fortin and Tremblay advocated the use of a short needle which 
was long enough to reach the plexus but too short to reach the 
lung, in an attempt to minimize the threat of pneumothorax. 
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History of Local Anaesthesia - Bupivacaine 
1. 1956 – Bupivacaine was synthesized by Ekenstam. 
2. 1963 – Bupivacaine was introduced into clinical practice by 
Telivuo. 
 
History of Tramadol 
1. 1970 - Tramadol was introduced by Grunenthal in German 
market. 
 
History of Peripheral Nerve Stimulator 
1. 1912 Perthes and 1955 Pearson - demonstrated peripheral 
nerve could be identified by electro stimulation. 
2. 1962 Greenblatt and Denson -introduced the nerve stimulator 
into clinical practice of anaesthesiology.  
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4. ANATOMICAL CONSIDERATIONS
3 
THE BRACHIAL PLEXUS: 
Knowledge of the formation of brachial plexus and of its 
distribution is absolutely essential for the use of brachial plexus 
anaesthesia for the upper limb surgeries. Close familiarity with the 
vascular, muscular and fascial relationships of the plexus throughout 
its formation and distribution is also essential to the mastery of the 
various techniques of brachial plexus blockade. 
 
In its course from intervertebral foramina to the upper arm, the 
fibres form roots, trunks, divisions, cords and terminal nerves passes 
through a complex process of combining, dividing, recombining and 
finally redividing. 
 
FORMATION OF PLEXUS 
Roots 
The plexus is formed by the anterior primary rami of the 
cervical nerves 5
th
 to 8
th
, together with the bulk of the thoracic nerve 
1
st
 (C8 and T1). In addition there is frequently a contribution above 
from C4 to the 5
th
 cervical root and another below fromT2 to the 1
st
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FIGURE 1 
THE RELATIONS OF THE BRACHIAL PLEXUS 
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thoracic nerve. Occasionally the plexus is mainly derived from C4 -8 
(Pre –fixed plexus) or from C6 – T2 (post – fixed plexus). 
 
Trunks and Divisions 
The five roots of the plexus emerge from the intervertebral 
foramina. They lie in the gutter between the anterior and posterior 
tubercles of the corresponding transverse process. All five roots then 
become sandwiched between scalenus anterior and medius. Here the 
roots of C5 and C6 unite to form the upper trunk. The root of C7 
continues as the middle trunk and those of C8 and T1 form the lower 
trunk. Each trunk then divides behind the clavicle, into anterior and 
posterior divisions, which unite to form the cords in the axilla. 
 
Cords: 
The six divisions unite up into three cords lateral, medial and 
posterior into the axilla. 
These cords are composed as follows: 
 The lateral cord is formed by the union of the anterior 
divisions of the upper and middle trunks. The anterior division of the 
lower trunk forms the medial cord. All the three posterior divisions 
form the posterior cord. 
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FIGURE 2 
BRANCHES OF BRACHIAL PLEXUS 
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DISTRIBUTION OF BRACHIAL PLEXUS 
These are divided with relation to clavicle - the supraclavicular 
branches that arise above the clavicle and the infraclavicular 
branches that arise below it. 
The composition of the brachial plexus can be summarized as 
follows: 
 
SUPRACLAVICULAR BRANCHES 
1. Five roots – the anterior primary rami of C5 – 8 and T1 
2. Three trunks. 
Upper trunk, C5 and C6 
Middle trunk, C7 alone and 
Lower trunk, C8 and T1 
3. Six divisions – each trunk divides into an anterior and 
posterior division.  
 
INFRACLAVICULAR BRANCHES 
      4. Three cords 
a) Lateral cord (C5 - C7) 
b) Medial cord (C8 - T1) 
c) Posterior cord (C5 - T1) 
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FIGURE 3 
A. CUTANEOUS DISTRIBUTION OF THE CERVICAL ROOTS.  
B. CUTANEOUS DISTRIBUTION OF THE PERIPHERAL NERVES 
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Branches are given off from 
1. Roots 
2. Trunks and 
3. Cords 
 
 Branches from the Roots 
  1. Nerve to the serratus anterior    (C5, C6 and C7) 
         2. Muscular branches to 
  i. Longus cervices    (C5- C8) 
  ii. Three scalene     (C5 – C8) 
  iii. Rhomboids     (C5) 
3. A twig of phrenic nerve    (C5) 
Branches from the trunks 
  1. Suprascapular nerve   (C5, C6) 
  2. Nerve to subclavius   (C5, C6) 
 
BRANCHES FROM THE CORDS 
LATERAL CORD 
Lateral pectoral nerve   (C5, C6, C7) 
Lateral head of median nerve   (C5, C6, C7) 
Musculocutaneous nerve   (C5, C6, C7) 
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FIGURE 4 
FORMATION OF BRACHIAL PLEXUS 
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MEDIAL CORD 
Medial pectoral nerve   (C8, T1) 
Medial head of median nerve  (C8, T1) 
Medial cutaneous nerve of arm  (C8, T1) 
Medial Cutaneous nerve of forearm (C8, T1) 
Ulnar nerve      (C7, C8, T1) 
POSTERIOR CORD 
Upper subscapular nerve   (C5, C6) 
Lower subscapular nerve   (C5, C6) 
Nerve to latissimus dorsi   (C6, C7, C8) 
Axillary nerve    (C5, C6) 
Radial nerve    (C5, C6, C7, C8, T1) 
 
SYMPATHETIC CONTRIBUTION TO BRACHIAL PLEXUS: 
The segmental preganglionic sympathetic contributions are 
variable, but generally extend more caudal. The highest contribution 
is usually from T2 with T1 contributing only rarely, while lowest 
may be as far as T8, T9 or even T10.The post ganglionic 
contributions are from grey rami communicantes from the 
sympathetic chain. 
 
 
21 
 
RELATIONS OF BRACHIAL PLEXUS: 
In its passage from the cervical transverse processes to the first 
rib, the plexus is "sandwiched" between the anterior and middle 
scalene muscles and invested in the fascia of those two muscles. 
 
The 'interfascial compartment', along with subclavian artery 
which crosses the first rib immediately infront of the trunks. Artery 
is close to the scalenus anterior and the plexus is close to the 
scalenus medius. Subclavian vein is separated from the artery by the 
scalenus anterior. The fascia covering the muscles is derived from 
the perivertebral fascia, which splits to invest these muscles and 
rejoins again at their lateral margins to form an enclosed space, the 
interscalene space. As the plexus cross the first rib, the three trunks 
are arranged one on top of the other vertically. Not infrequently, the 
inferior trunk gets trapped behind and even beneath the subclavian 
artery above the rib, during embryologic development. 
 
This may be the reason why local anaesthetics injected via the 
interscalene techniques sometimes fail to provide anaesthesia in the 
distribution of the ulnar nerve, which may be buried deep within 
inferior trunk behind or beneath the subclavian artery. After crossing 
the first rib, they the split to form divisions and the cords and 
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subclavian artery becomes the axillary artery. Above the clavicle, the 
axillary artery lies central to the three cords, in the axilla the lateral 
and posterior cords are lateral to the first part of the axillary artery, 
the medial cord being behind it. Around the second part of the artery, 
they are related according to their names. In the lower axilla, cords 
divide into nerves for the upper limb.  
 
In passing over the first rib under the clavicle, the subclavian 
vein also becomes the axillary vein and its relationship with the 
neurovascular bundle changes. Above the first rib the subclavian 
vein does not lie within the neurovascular bundle, it is separated by 
the insertion of scalenus anterior. As it passes over the first rib, 
becoming the axillary vein it joins the neurovascular bundle so that 
parts of the plexus are sandwiched between artery and vein. As all 
the three enter the axilla, they invaginate the perivertebral fascia at 
the lateral margins of the anterior and medial scalene muscles, 
carrying this fascial investment of the neurovascular bundle into the 
axilla as the axillary fascia, an extension of the perivertebral or 
scalene fascia forming the axillary perivascular space, a tubular 
extension of the interscalene space. In its course through the axilla 
and upper arm the fascia of the surrounding muscles contribute to the 
axillary sheath, making it thick and tough, providing the 'fascial 
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FIGURE 5 
SHEATH AROUND THE PLEXUS  
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click' to the anaesthetic while entering the sheath. It is 
important to note that major terminal nerves leave the sheath high in 
the axilla under the cover of pectoralis minor muscle. 
 
The musculocutaneous nerve enters the substance of 
coracobrachialis and continues down within this muscle. The axillary 
nerve also leaves the sheath immediately after arising from the 
posterior cord. The interocostobrachial nerve travels parallel to but 
outside the axillary sheath and medial cutaneous nerve of the arm 
runs similarly but occasionally it may remain within the sheath. 
 
THE BRACHIAL PLEXUS SHEATH 
 The connective tissue of the prevertebral fascia and the 
anterior and middle scalenus envelops the brachial plexus as well as 
the subclavian and axillary artery in a neurovascular "sheath". 
Volume of the sheath: 42ml. 
Shape of the sheath: Cylindrical to conical - Wide proximally 
and narrow distally. 
Length: 8-10cms. 
The tissue is densely organized as it leaves the deep cervical 
fascia proximally, but becomes more loosely arranged distally. The 
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sheath blends with the fascia of the biceps and brachialis muscle 
distally. 
 
Anaesthetic implications 
Because of these connective tissue septae, anaesthesia might 
be complete and rapid in onset in some nerves, but delayed and 
incomplete or completely absent in others. The incidence of partial 
block is an exception rather than the rule, so septa apparently are of 
little clinical significance as the local anaesthetic can percolate 
through them. 
 
TECHNIQUE OF BRACHIAL PLEXUS BLOCK 
 
Surgical anaesthesia of the upper extremity and shoulder can 
be obtained following neural blockade of the brachial plexus at 
several sites. The various approaches that can be used for this 
blockade are as follows. 
1. Interscalene approach 
2. Supraclavicular approach 
a. Classic approach 
b. Plumb –bob technique 
c. Subclavian perivascular technique 
3. Axillary approach 
4. Infraclavicular approach. 
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TECHNIQUE OF BLOCKADE - SUPRACLAVICULAR 
SUBCLAVIAN PERIVASCULAR APPROACH TO 
BRACHIAL PLEXUS 
Anatomical Land marks:  
The three trunks are clustered vertically over the first rib 
cephaloposterior to the subclavian artery. Neurovascular bundle lies 
inferior to the clavicle at above its mid point. 
The essential landmarks to be identified are 
1. Cricoid cartilage 
2. Interscalene groove 
3. Clavicle midpoint 
4. Subclavian artery 
 
PROCEDURE: 
Position: Supine position with the head turned to the opposite side to 
be blocked. The arm is pushed down to depress the clavicle.  
The posterior border of sternocleidomastoid is felt, by asking 
the patient to raise the head while keeping the head turned to 
opposite side. The interscalene groove should be located behind the 
midpoint of the posterior border of the muscle. The anterior and 
middle scalene muscles can be made prominent by asking the patient 
to inspire vigorously. Approximately 1 cm above the midpoint of the 
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clavicle the pulsation of the subclavian artery can be felt in the 
interscalene groove while standing on the side of the patient. On the 
right side interscalene groove is palpated with the left index finger 
and the needle is inserted with the right hand. Subclavian artery is 
guarded with thumb. After aseptic measures and intradermal weal 
raised with local infiltrations of 1 ml of 2% Lignocaine intradermally 
in the interscalene groove 1 to 1.5 cm above the clavicle, a 22G, 50 
mm short bevelled unipolar insulated needle connected to a nerve 
locator is directed posteriorly and caudally towards the ipsilateral 
nipple and slightly medially. End point in a nerve stimulator is a 
motor response in ulnar distribution side of hand with an output less 
than or equal to 0.5mA. To avoid intra vascular injection aspiration 
done every 3-5 ml of the drug injected.within one ml of injection 
muscular twitch disappear. The solution should flow without 
resistance. High resistance or pain on injection may indicate 
intraneural injection and the needle must be repositioned. 
 
Volume of local anaesthetic (either 1% lignocaine or 0.25% 
Bupivacaine) that can be used is 25-40 ml depending on the weight 
of the patients. When large volumes are used the sheath may be felt 
to distend during injection and is easily distinguished from the 
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subcutaneous swelling of an extra fascial injection. To encourage the 
spread proximally, digital pressure distal to the needle point may be 
used and digital pressure proximal to needle insertion point may help 
to encourage distal spread. 
 
COMPLICATIONS 
a) Related to procedure 
 Vessel puncture - Haematoma formation 
 Pneumothorax 
 Neuropraxia 
b) Related to Local anaesthetic 
 Intravascular injection 
 Circumoral numbness 
 Convulsions 
 Cardiac arrest 
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5. PHYSIOLOGICAL CONSIDERATIONS
4 
 
International association for the study of pain has defined pain as 
“An unpleasant sensory and emotional experience associated with 
actual or potential tissue damage, or described in terms of such 
damage”. 
 
Pain perception requires a noxious stimulus which is transformed 
from its native form by the activated nociceptors into electrical 
signals which are then transmitted along the corresponding 
nociceptive fibres. These fibres in turn synapse onto second order 
neurons in the spinal cord. These interneurons are located in the 
dorsal horn. It is at these interneurons where the initial modulation of 
nociceptive input occurs. From the spinal cord nociceptive input is 
transmitted to the brain stem, thalamus and cortex. 
 
Peripheral neuroanatomy of nociception 
C and A fibres are the main peripheral nociceptors. The skin, 
joints and periosteum are richly innervated with C and A nociceptors 
as well as the non nociceptive AB sensory fibres. 
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A fibres are responsible for the sensation of first pain, the initial 
sharp pain experienced following an injury. C fibres are 
unmyelinated and are responsible for second pain, the slowly 
building throbbing burning pain experienced following an injury. 
 
Classification of sensory fibres 
Sensory 
receptors 
Speed of 
transmission 
Sensory function Myelination 
C fibres 0.5 – 2 m/sec1 
Noxious chemical, 
mechanical, thermal 
activation (slow burning 
second pain) 
Unmyelinated 
Aα fibres 70 – 120m/sec 
noxious chemical thermal,  
mechanical stimuli (sharp 
fast, first pain) 
slightly 
myelinated 
Aβ fibres 30 – 70 m/sec 
nonpainful, light touch, 
pressure, vibration, 
proprioception 
heavily 
myelinated 
Aγ fibres 30 – 70 m/sec 
proprioception, motor to 
muscle spindle 
myelinated 
Aδ fibres 12 – 30 m/sec pain, cold, touch myelinated 
B fibres 3- 15 m/sec 
pre ganglionic autonomic 
(sympathetic) 
myelinated 
 
Peripheral neurochemistry and neurotransmitters 
 Commonly released inflammatory mediators implicated in 
pain and hyperalgesia include bradykinins, potassium, substance-P, 
cytokines, histamine, serotonin and prostaglandins. These peripheral 
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neurotransmitters either activate or sensitize the peripheral 
nociceptors to pain. 
 
Peripheral neurochemistry of Algogenic agents: 
Algogenic agent Action on nociceptors 
Bradykinin activates 
Substance P sensitizes 
Potassium activates 
Hydrogen activates 
Arachidonic acid sensitizes 
Cytokines sensitizes 
Serotonin sensitizes 
Noradrenaline 
high concentration activates and 
sensitizes after injury. 
 
Physiology of nerve conduction 
Neurons are the basic building blocks of the nervous system 
that responds to various stimuli. Integration and transmission of 
nerve impulses are specialized functions of neurons. 
 
All peripheral nerves are elongated axons of neurons situated 
centrally. A typical peripheral nerve consists of bundles of motor, 
sensory and other fibres enclosed in the outermost covering called 
epineurium. Each nerve fibre in a bundle is enclosed in a layer of 
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neurilemma or the axonal membrane. Depending upon the presence 
or absence of myelin sheath, it can be a myelinated nerve fibre or 
unmyelinated fibre. 
 
The axonal membrane itself is made up of a bimolecular lipid 
palisade, interspersed with large protein molecules. The membrane 
lipids are largely phospholipids composed of a polar head group and 
a non polar hydrocarbon tail. 
 
The primary function of the cell membrane is to separate the 
extracellular from the intracellular environment. The major 
difference between these two environments is the ionic 
concentration. This disequilibrium provides the means for impulse 
conduction. 
 
The most important ions in this respect are sodium and 
potassium. A membrane bound protein sodium potassium ATPase 
maintains normal resting equilibrium potential between -50mv to - 
90mv by pumping potassium ions into the cell and sodium ions out 
of the cell. A positive ion gradient from inside the membrane to 
outside causes electronegativity inside the membrane. 
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During nerve conduction the following changes occur in the 
cell membrane. 
 
In the resting phase: 
There is a potential difference across the membrane the inside 
is negative, due to a higher concentration of sodium ions outside than 
inside the cell. 
 
Na
+ 
moves in and K
+ 
moves out of cells but because of more 
K
+
 channels opened at rest, K
+
 permeability is greater than Na+ 
permeability. Therefore K+ channels maintain the resting membrane 
potential. 
 
Depolarization phase:  
During excitation, Na+ channels in the cell membrane open 
briefly allowing sodium ions to flow into the cell, thereby 
depolarizing the membrane. 
 
Repolarization Phase: 
During this phase, opening of voltage gated K+ channel 
occurs, results in passing of potassium ions out of the cell to restore 
electrical neutrality. 
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Restoration Phase: 
During this phase, sodium ions return to the outside and 
potassium ions re - enter the cell. 
 
Distribution of ion channels in Myelinated Neurons: 
Voltage gated Na+ channels are highly concentrated in the 
nodes of Ranvier and the initial segment in myelinated neurons.  
 
The initial segment and in sensory neurons, the first node of  
Ranvier are the sites where impulses are normally generated and the 
other nodes of Ranvier are the sites to which the impulses jump 
during saltatory conduction. 
 
The sodium channel is believed to be an integral membrane 
spanning protein. Depolarization of the cell induces a configurational 
change on the sodium channel which causes it to open and allow ion 
passage. In many myelinated neurons, the Na+ channels are flanked 
by K+ channels that are involved in repolarization. 
 
Action of Local Anaesthetics on Nerve Fibres
5
: 
The primary action of local anaesthetics on the nerves is 
electrical stabilization. The large transient increase in permeability to 
Na+ ions necessary for propagation of the nerve impulse is 
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prevented. Thus the resting membrane potential is maintained and 
depolarization in response to stimulation is inhibited. 
Local anaesthetics block sodium conductance by:                                  
1. binding of local anaesthetics to sites on voltage gated Na+ 
channels prevents opening of the channels by inhibiting the 
conformational changes that underlie channel activation. 
2. local anaesthetics produce nonspecific membrane expansion. 
There is an unfolding of membrane protein together with a 
disordering of the lipid component of the cell membrane with 
consequent obstruction of the sodium channel.  
 
PAIN PATHWAY 
SPINAL CORD 
 The gray matter of the spinal cord is divided into ten lamina 
with lamina   I – IV representing the dorsal horn. The dorsal horn is 
capped by the Lissauer’s tract which consists of branches of 
cutaneous A and C – fibres and few visceral afferents. 
 
Nociceptive fibres terminate in the superficial layers of lamina 
I & II while the non-painful myelinated fibres terminate in the deeper 
layers of lamina III, IV. Lamina II has the highest concentration of 
opioid receptors in the spinal cord. Modulation and inhibition of 
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nociception may occur at this level through the use of opioids 
(systemic and neuraxial). 
 
Ascending sensory pathways 
 Peripheral sensory neurons synapse onto the secondary 
interneurons of the dorsal horn. The axons of the non nociceptive 
secondary neurons travel isobilateral in the dorsal columns of the 
spinal cord as fasciculus cuneatus (upper body through T6) and 
fasciculus gracilis (lower body below T6) and synapse in the 
thalamus. 
 
 The axons of the nociceptive secondary neurons after 
synapsing travel contra laterally in the anterolateral aspects of the 
spinal cord as the neospinothalamic and paleospinothalamic tract. 
 
 Neospinothalamic tract carries fine discrimination of pain e.g. 
location, intensity, and first pain. 
 
 Paleospinothalamic tract responds to noxious stimuli. The 
paleo spinothalamic tract synapses in the thalamus, hypothalamus 
and limbic system and plays a role in emotional aspects of pain via 
limbic system. The thalamus has multiple connections to limbic 
system and cortex. 
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Descending inhibitory pathways 
The descending controls of pain project specifically onto 
laminas I, II, V of the dorsal horn from mesencephalon, raphenuclei 
and reticular tract. The mesencephalon is rich in opioid receptors. 
This area sends excitatory transmissions to the rostroventral medulla 
which sends noradrenaline and serotonin inhibitory tracts via the 
dorsolateral funiculus to lamina I, II, V of spinal cord. 
 
 The noradrenaline and serotonin fibres mediate transmission 
between the primary afferents and the secondary neurons of the 
dorsal horn. Increased activity of these fibres leads to increased 
inhibition of pain transmission. 
 
Location of opioid receptors (central) 
 Opioid receptors are found in the various regions in CNS 
namely, cerebral cortex, limbic cortex (anterior and posterior 
amygdale, hippocampus) hypothalamus, medial thalamus, mid brain, 
periaqueductal gray matter, extrapyramidal areas, substantia 
gelatinosa and sympathetic preganglionic neurons. 
 
 Opioid receptors are also found in the cardiac sympathetic 
fibres, cardiac branches of vagus, adrenal medulla, and gastro 
intestinal tract. 
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6. BASICS OF NERVE LOCATOR
6, 7 
 
Perivascular technique and elicitation of paraethesia had been 
the classical methods for locating nerves in peripheral nerve blocks. 
Peripheral nerve locator technology is a newer one, utilizing 
objective end points for effective nerve localization. 
 
Peripheral nerve locator is used to elicit Evoked Motor 
Response (EMR). They are used to assess functioning of 
Neuromuscular (NM) junction. The other name for Peripheral nerve 
locator (PNL) is Peripheral nerve stimulator (PNS) .When the high 
intensity current is used to assess the NM junction function through 
cutaneous electrodes it is called as PNS. When low intensity current 
is used to locate the nerve it is called peripheral nerve locator. 
 
Physiological basis of PNL Technology 
The ability of a nerve locator to evoke a motor response 
depend on i) intensity of current 
ii) duration of current 
iii) polarity of stimulating current used  
iv) needle nerve distance. 
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Assuming a square pulse of the current is used to stimulate the 
nerve the total charge applied is the product of intensity of current 
and duration of the pulse. 
 
Rheobase and Chronaxie: 
Rheobase is the minimal current required to stimulate the 
nerve with a long pulse width. 
Chronaxie is the duration of the stimulus required to stimulate 
at twice the rheobase. 
  I = Ir (1+c/t) 
Where  I - current required,  C - chronaxie, 
  Ir - rheobase,   t - duration of stimulus. 
Chronaxie is useful when comparing different nerves or nerve 
fibre types. The larger fibres are more readily stimulated than the 
smaller fibres. It is possible to stimulate the larger Aα motor fibre 
without stimulating the smaller Aδ or C -fibres responsible for pain. 
 
Chronaxies of Peripheral Nerves 
 * A-α     50 -100 μ seconds 
 * A-δ    170 μ seconds 
 * C-Fibres    400 μ seconds 
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Principles of peripheral nerve stimulation: 
i) Preferential cathodal stimulation: 
Significantly less current is needed to obtain a response to 
nerve stimulation when cathode is adjacent to the nerve, rather than 
the anode. 
ii) Variation of stimulus intensity with varying needle nerve distance. 
Stimulation intensity will be variable as determined by 
Coulomb’s law.The relationship between the stimulus intensity and 
the distance from the nerve is governed by Coulomb’s law 
I = K (Q/r
2
) 
Where I is the current required to stimulate the nerve, K is a 
constant, Q is the minimal current needed for stimulation, and r is the 
distance from the stimulus to the nerve.. A very high stimulus current 
is required to stimulate the nerve when the needle tip is far away 
from the nerve. 
 
Components of peripheral nerve locators 
 Oscillator  
 Display 
 Constant current generator 
 Controls. 
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Characteristics of an ideal PNL 
1) Constant current output:- 
The constant current designs of the locator allows for an 
automatic compensation for changes in tissue or connection 
impedance during nerve stimulation assuring accurate delivery of the 
specified current. 
 
2) Options for different pulse width:- 
Shorter pulse width corresponds to the chronaxie of motor 
fibres in a mixed peripheral nerve. Wider pulse width (>100μ sec) is 
useful for stimulating a sensory nerve or a nerve with compromised 
conduction i.e. Diabetic neuropathy. 
 
3) A wide range of current output - 0.01 to 5.0 mA:- 
A higher current output is needed for patients with neuropathy 
and sensory nerve   stimulation. 
 
4) Digital display of the delivered current. 
5) Variable current output dial. 
6) Clearly identifiable polarity 
7) Disconnect indicator - shows circuit connection status 
8) Battery indicator 
9) Stimulating frequency:- 
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If the stimulating frequency is higher, it allows faster 
manipulation of the needle. 
 
Clinical points to be noted while using PNL: 
An effective use of PNL technology mandates knowledge of 
anatomy with respect to 
a) Optimal needle insertion site to achieve needle tip – target nerve 
contact. 
b) Muscle innervations scheme of the targeted nerve to identify 
desired evoked motor response (EMR). 
c) Ability to differentiate desired EMR from the alternate EMR 
elicited by the stimulation of adjacent muscle and collateral nerves. 
d) The relationships of adjacent neuromuscular structures generating 
those alternate EMR to the targeted nerve. 
e) The highest rate of success is attained when a brisk EMR occur 
between 0.2-0.4mA. 
An EMR at currents higher than 0.5mA may result in failed 
block because the needle tip is too far from the nerve. A brisk EMR 
at stimulating current lower than 0.1mA may risk nerve damage 
because of the possibility of an intraneural injection. 
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Peripheral Nerve Locator Settings: 
1) Mixed nerve (most PNB) 
Current      1 mA 
Current duration (Pulse with)      0.1ms 
Frequency     1-2 HZ 
2) Sensory nerve (e.g. lateral cutaneous and saphenous nerve) 
Current      2-5 mA 
Current duration      1ms 
Frequency      1 Hz 
3) Diabetic neuropathy (PNB) 
Current       2 mA 
Current duration      0.3 ms 
Frequency      1-2 Hz 
 
APPROPRIATE EVOKED MOTOR RESPONSE FOR EACH 
PNB 
PNB Technique Optimal EMR 
Interscalene 
Flexor: Deltoid, Biceps, Pectoralis major 
Extensor: Triceps, Brachioradialis, Wrist 
extensors (EMR of  > 2 muscles) 
Deep Cervical 
plexus 
Rhomboids, Shoulder girdle 
Infraclavicular 
Muscles of wrist and hand 
Radial – extension of wrist/ fingers. 
Median – flexion of wrist / fingers. 
Ulnar – adduction of thumb / 4th and 5th finger 
flexion. 
Femoral Quadriceps – patellar tap 
Sciatic Inversion, plantar flexion of the foot 
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7. PHARMACOLOGY OF BUPIVACAINE
8, 9, 10 
 
BUPIVACAINE  
Bupivacaine is a local anesthetic agent with long duration of 
action 
 
Pharmacology 
Bupivacaine hydrochloride is 2 piperidine carboxamide, 1 
butyl N-2, 6 dimethyl phenyl, monohydrochloride, and monohydrate.  
 
Bupivacaine molecule is a tertiary amine separated from an 
aromatic ring system that is a benzene ring by an chain. The tertiary 
intermediate amine is a base that is a proton acceptor. The chain 
contains an amide linkage (-NHCO-) hence it is classified as an 
amino amide compound. This amide linkage contributes to the 
anesthetic potency.  
 
The aromatic ring system gives a lipophilic character to its 
portion of molecule whereas the tertiary amine end is relatively 
hydrophilic.  
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STRUCTURE 
 
 
Structure - Activity relationship:  
Bupivacaine being more lipophilic (because of butyl group) it 
is very potent and produces longer lasting blocks. 
 
PHARMACODYNAMICS 
 Mechanism of action: 
 The uptake of the drug by the tissues is largely due to 
lipophilic absorption. This shifts effective pKa downward and 
thereby favors the neutral base form. 
 
 Bupivacaine blocks impulses by reducing the currents through 
voltage-activated Na+ channels. The inhibition is not specific; 
however, K+ currents are also reduced. Binding of bupivacaine to 
sites on voltage gated Na+, channels prevents opening of the 
channels by inhibiting conformational changes. 
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It is similar to that of any other local anaesthetics. The primary 
action of local anaesthetics is on the cell membrane of the axon, on 
which it produces electrical stabilization. The large transient increase 
in permeability to sodium ions necessary for propagation of the 
impulse is prevented. Thus the resting membrane potential is 
maintained and depolarization in response to stimulation is inhibited. 
The mechanism by which local anaesthetics block sodium 
conductance is as follows: 
 
a) Local anaesthetics in the cationic form act on the receptors 
within the sodium channels, on the cell membrane and blocks it. The 
local anaesthetic can reach the sodium channel either via the 
lipophilic pathway directly across the lipid membrane, or via the 
axoplasmic opening. This mechanism accounts for 90% of the nerve 
blocking effects of amide local anaesthetics. 
b) The second non specific mechanism of action is by 
membrane expansion. 
 
PHARMACOKINETICS:  
 Pka 8.1 
 Bound in plasma 95% 
 Clearance 7.1 – 2.8 ml/kg/min 
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 Volume of distribution 0.4 – 0.9 litres / kg 
 Half life 1.2 – 2.4 hours 
 Peak time 0.17 – 0.5 hours 
 Peak concentration 0.8 micrograms/ml 
 Toxic plasma concentration >1.5 micrograms/ml 
 Clearance – 0.47 litres /min 
 Metabolism – Liver by dealkylation to 
Pipecolyloxilidine 
 Excretion – 5% by the kidney as unchanged drug 
and the rest as metabolites. 
TABLE: 4. Dosage and concentration of Bupivacaine in various 
block 
Type of Block Concentration Dosage ml Dosage mg 
Local infiltration 0.25 – 0.5% 5 – 20 ml upto 175mg 
Brachial plexus 
block 
0.25 – 0.5% 20 – 40 ml 75 – 225mg 
Intercostal nerve  
block 
0.25 – 0.5% 3 – 5 ml 
15 – 20 mg per 
each nerve 
Epidural block 0.25 – 0.5% 15 – 20 ml 50 – 200mg 
Caudal block 0.25 – 0.5% 15 – 30 ml 75 – 150mg 
Subarachnoid 
block 
0.5% 2 – 4 ml 10 – 20mg 
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DRUG DOSAGE
11, 12
 
 
Bupivacaine upto 3mg/kg. 
Addition of epinephrine to bupivacaine has no effect on its 
duration of action but it delays absorption of local anaesthetic due to 
vasoconstriction from the site of administration. 
 
Toxicity of Bupivacaine 
It is relatively free of side effects if administered in an 
appropriate dosage. It is more cardiotoxic than Lignocaine and this is 
made worse by hypoxia, hypercapnia, acidosis and pregnancy. 
 
1.  Central nervous system toxicity 
  CNS is more susceptible to bupivacaine. The initial symptoms 
involve feeling of light headedness and dizziness followed by visual 
and auditory disturbance. Disorientation and occasional feeling of 
drowsiness may occur. Objective signs are usually excitatory in 
nature which includes shivering, muscular twitching and tremors; 
initially involving muscles of the face (perioral numbness) and part 
of extremities. At still higher doses cardiovascular or respiratory 
arrest may occur. Acidosis increases the risk of CNS toxicity from 
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Bupivacaine, since the elevation of PaCO2 enhances cerebral blood 
flow, so that more anesthetic is delivered rapidly to the brain.  
  
2. Cardiovascular system toxicity   
Bupivacaine depresses rapid phases of depolarization (Vmax) 
in purkinge fibres and ventricular musculature to a greater extent 
than lignocaine. It also decreases the rate of recovery from a 
dependent block than that of lignocaine. This leads to incomplete 
restoration of Vmax between action potential at high rates, in 
contrast to complete recovery by lignocaine. This explains why 
lignocaine has antiarrhythmic property while bupivacaine has 
arrhythmogenic potential. High level of bupivacaine prolongs 
conduction time through various parts of heart and extremely high 
concentration will depress spontaneous pacemaker activity, resulting 
in bradycardia and arrest. Cardiac resuscitation is more difficult 
following bupivacaine induced cardiovascular collapse and hypoxia 
along with acidosis which markedly potentiates cardiac toxicity. 
Bretylium raise the ventricular tachycardia threshold that was 
lowered by bupivacaine but not by lignocaine.  
 
50 
 
The cardiovascular collapse / central nervous system ratio for 
bupivacaine is 3.7  0.5. 
 
3. Respiratory system:  
Respiratory depression may be caused if excessive plasma 
level is reached which in turn results in depression of medullary 
respiratory center.  
 
4. Autonomic nervous system: 
  Myelinated preganglionic beta fibers have a faster conduction 
time and are more sensitive to the action of local anesthetic including 
bupivacaine. Involvement of preganglionic sympathetic fibers is the 
cause of widespread vasodilatation and consequent hypotension that 
occurs in epidural and paravertebral block. When used for 
conduction blockade all local anesthetic agents particularly 
bupivacaine produces higher incidence of sensory blockade than 
motor fibers. 
 
Treatment of adverse reaction: 
Treatment is mainly symptomatic i.e. maintaining circulation 
with IV fluids and vasopressors if required to restore the 
cardiovascular stability and to support ventilation with oxygen or 
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controlled ventilation. Convulsions may be controlled with diazepam 
(0.1- 0.2 mg/kg) or thiopentone (2-3 mg/kg) or a muscle relaxant and 
controlled ventilation with oxygen. Corticosteroids, if allergic 
reactions are suspected. Treatment of ventricular fibrillation and 
tachycardia by amiodarone (5mg/kg IV), bretylium (5mg/kg) or 
defibrillation (2-6 joule/kg). 
 
Role of additives: 
i. Adrenaline: Onset time reduced and duration prolonged. 
ii. Sodium bicarbonate: Onset time reduced and duration 
variable. 
iii. Clonidine: Onset time reduced and duration prolonged. 
iv. Hyaluronidase: Onset time reduced and duration variable. 
v. Opioids: Onset time reduced and duration prolonged. Reports 
controversial. 
vi. Midazolam: Onset time reduced and duration prolonged. 
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8. PHARMACOLOGY OF TRAMADOL
13, 14, 15, 16 
 
Tramadol is an analgesic with unique dual mechanism. It is a 
synthetic 4 – phenyl piperidine codeine analogue. Tramadol is a 
racemic mixture of 2 enantiomers. 
 
Structure of Tramadol 
 
• Chemical name: Tramadol belongs to the aminocyclohexanol 
group. 
 
Mechanism of action 
Tramadol has both opioid and non-opioid actions 
1. Tramadol has a low affinity for opioid receptors. It acts as a 
selective μ-receptor agonist, but also binds weakly to kappa and delta 
receptors. 
2. Non-opioid mechanism is by monoaminergic pathway. It inhibits 
noradrenaline and 5-hydroxy tryptamine (serotonin) neuronal 
reuptake and facilitates serotonin release. The two enantiomers of 
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tramadol i.e., tramadol (+) and tramadol (-) have complementary and 
synergistic anti-nociceptive interaction. Tramadol (+) has greater 
affinity for μ receptors and inhibits serotonin reuptake. Tramadol (-) 
inhibits norepinephrine reuptake. The synergistic effect of both these 
enantiomers may be responsible for its low potential for the 
development of tolerance, dependence, and abuse and production of 
analgesia with the absence of ventilatory depression. Interestingly, 
the racemate may produce less sedation and gut inhibition than either 
enantiomer alone. 
 
Pharmacodynamics 
Effects on respiration  
In clinically recommended doses, tramadol is unlikely to 
produce relevant respiratory depression. 
 
Effects on cardiovascular system 
 Tramadol increases transiently heart rate, both systolic and 
diastolic blood pressure; it increases peripheral vascular resistance, 
decreases pulmonary arterial resistance, and exerts a negative 
inotropic effect on left ventricular myocardium. 
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Tolerance and dependence 
Tolerance is minimal. It has low physical and psychological 
dependence. 
 
Other effects 
 Tramadol in clinical dosage has no effect on plasma histamine 
levels and it does not cause any systemic anaphylactoid reactions.  
 
Pharmacokinetics 
 Bioavailability  
Oral 68 %( 70 – 75%) 
Intramuscular 100% 
 Elimination T1/2 6hours (4.5 – 7.5%) 
 Metabolite 7.5hours 
 Percentage of drug bound in plasma 20% 
 Clearance 8ml/min/kg (6 – 12ml) 
 Volume of distribution 2.7litres/kg (2.3 – 3.9) 
 Onset of analgesia 1 hour 
 Peak time 2.3 ± 1.4 hours 
 Peak concentration 592 ± 178 nanogram /ml in blood 
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 Metabolism – Liver by O- demethylation to O- 
desmethyl tramadol which shows 200 times higher 
affinity for µ receptors. 
 Elimination – 15 – 30% as unchanged drug by kidney. 
 
Therapeutic efficacy  
On intravenous administration, tramadol is equivalent to 
pethidine, l/5th as potent as nalbuphine, 1/10th as potent as 
morphine. 
 
Dosage  
Tramadol can be given in doses of 50-100 mg upto 4 times a 
day. Total daily dose should not exceed 400mg for adults. In children 
> l year of age the dosage is 1 – 2 mg/kg. 
 
Routes of administration 
 Oral, parenteral, epidural, rectal, caudal. 
Adverse effects: Mild, transient and rare 
1. CNS: Nonspecific CNS irritation, dizziness, sedation, euphoria, 
    dysphoria. 
2. GIT: Nausea, vomiting, constipation, GI irritation 
3. ANS: Dry mouth, sweating (due to its monoaminergic effects) 
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4. CVS: Orthostatic hypotension, tachycardia 
5. Others: Motor weakness, urinary retention 
Respiratory depression with tramadol is less than that with 
morphine. Respiratory depression is unusual in recommended doses 
and was not found in neonates whose mother had been given 
tramadol. The advantage of tramadol over other opioids with respect 
to less respiratory depression is limited by lack of efficacy of 
tramadol in severe pain. 
 
Drug interactions 
Tricyclic antidepressants, selective serotonin reuptake 
inhibitors (SSRI), neuroleptics: tramadol when given to patients on 
these drugs decreases the seizure threshold. Concomitant 
administration of tramadol and SSRI causes serotonin syndrome. 
 
Concomitant administration of tramadol with monoamino 
oxidase inhibitors causes hypertensive reactions. Quinidine inhibits 
tramadol metabolism. Hence serum tramadol concentration 
increases, when these 2 drugs are used. Carbamazepine enhances 
tramadol metabolism, hence tramadol halflife is decreased as much 
as 50%. When these two drugs are used concomitantly, tramadol 
dose should be increased. 
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Overdosage: 
 Symptoms are similar to other opioids. Miosis, vomiting, 
coma, 
respiratory depression, respiratory arrest and cardiovascular collapse. 
Opioid antagonist naloxone will reverse coma and respiratory 
depression. 
 
Advantages: 
1. Can be given through different routes - oral, parenteral etc. 
2. Less respiratory depression 
3. Less dependence, abuse, tolerance 
4. Less secretion in the milk of lactating mother. 
5. Freely available. No narcotic prescription restriction. 
6. Comparatively cheap. 
 
Indications: 
1. Tramadol is indicated for moderate to severe pain in adults. 
Tramadol 50-150 mg IV was equivalent to morphine 5-15 mg but a 
preservative free preparation had 1/13 of the potency of morphine 
extradurally. 
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Despite being relatively less potent than pure opioids, 
tramadol has achieved efficacy when used to treat moderate pain 
after surgery. Because of its efficacy as an analgesic, tramadol is 
considered to be effective in step two of the world health 
organization guideline for treatment of patients with cancer pain. 
2. In peripheral nerve blocks along with local anaesthetics to prolong 
the duration of anaesthesia as well as analgesia. 
 
Contraindications: 
As tramadol enhances monoaminergic transmission, the drug 
is contraindicated in patient receiving mono-amino oxidase inhibitors 
and caution  advised  in patients with epilepsy. Not recommended in 
children <1 year. 
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9. REVIEW OF LITERATURE 
 
1. Suman Chattopadhyay et al 2007
17
 conducted a prospective 
double blind study in supraclavicular brachial plexus block to 
evaluate the effect of weak opioid tramadol with nonopioid 
mechanisms of action, improves post operative analgesia when used 
as an additive along with bupivacaine in 70 patients who underwent 
surgery of various upper limb surgeries. These patients are randomly 
allocated into 2 equal groups  so that 35 patients received inj. 
bupivacaine (0.25%) - 38 ml + 2 ml normal saline (Group C) and the 
remaining 35 received  inj. bupivacaine (0.25%) - 38 ml +tramadol 
100 mg (2 ml) (Group T) [total volume in both group 40 ml].The 
onset, quality and duration of the block and duration of analgesia 
was assessed as well as the possible side effects and also the 
incidence of various complications following the procedure. Earlier 
the onset of motor (6.1 ± 1.2 vs 8.6 ± 1.4 mins) and sensory 
blockade(11.2 ± 2.1 vs 18.4 ±  2.5mins) and the duration of pain 
relief (410.1 ± 95.1 min vs 194.8 + 60.4 min) produced with addition 
of  tramadol was longer and superior  in comparison to control group 
(p<0.05).  Tramadol group also demonstrated no changes in pulse 
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rate, blood pressure and spo2. No side effect was noted in any of the 
patients. Tramadol is a useful adjuvant for brachial plexus block. 
 
2. Renu Wakhlo et al 200918 conducted a study on 60 patients to 
compare the adjuncts- tramadol and butorphanol to lignocaine with 
adrenaline for onset and duration of block and post operative 
analgesia for upper limb surgeries following supraclavicular brachial 
plexus block. All patients received total volume of 30 cc of 
anaesthetic. Patients were randomly divided into three equal groups 
so that 20 patients received only lignocaine with adrenaline 
(1:200,000 ) 20 cc and 10 cc saline (Group I), next 20 patients 
received lignocaine with adrenaline + tramadol 100 mg (2 cc) +8cc 
saline (Group II) and remaining 20 received lignocaine + adrenaline 
+ butorphanol 1 mg. (1 cc) + saline 9 cc (Group III). The onset of 
sensory and motor block, duration of block and post operative 
analgesia was compared. Statistical analysis was done by ANOVA 
test and intergroup comparison done by Bonferroni's t test. It was 
found that Group II patients had earlier onset and prolonged duration 
of sensory and motor block while Group III patients had prolonged 
duration of postoperative analgesia lasting upto mean of 12 hours. 
Thus tramadol was found to be good agent for hastening the onset 
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and prolonging the sensory and motor block while butorphanol is 
suitable agent for prolonged postoperative analgesia. 
 
3. S.Antonucci et al 2001
19
 compared the adjuvant effects of 
Clonidine (1.5 mcg/kg), Sufentanil (20 mcg) and Tramadol (100mg) 
with 0.75% Ropivacaine in brachial plexus axillary blockade among 
80 patients of  each group20 with control group as normal saline and 
concluded that the use of tramadol 100mg as adjuvant provides a 
significant reduction of onset time and  provides a prolonged 
anaesthesia and analgesia with a quality of block similar to that of  
Clonidine and Sufentanil and incidence of side effects like sedation, 
bradycardia and hypotension and itch are lower. They concluded that 
tramadol 100mg may be a useful alternative as adjuvant in periphery 
block with same effects of other drugs commonly used and a lower 
incidence of side effects. 
 
4.Sukran Geze et al 2012
20
 compared tramadol 100mg and fentanyl 
50mcg by adding to 40ml of 0.25% levobupivacaine plus 40mg 
lignocaine mixture for axillary plexus block by randomized double 
blind study and concluded that tramadol hydrochloride or fentanyl 
when added to local anaesthetic mixtures as an adjuvant agent 
provide better postoperative analgesia in axillary block for 
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orthopaedic upper limb surgeries. Furthermore tramadol improves 
the block quality more than fentanyl.  
  
 5. Shrestha BR et al 2007
21
 evaluated the postoperative analgesia 
of tramadol 2mg/kg and dexamethasone 8mg as admixture to 
bupivacaine by conducting a prospective, randomized, double blind 
study in 60 patients. Patients were randomly allocated in to two 
groups of 30 each. The duration of postoperative analgesia was 
recorded in both groups using pain VAS score which was determined 
by maximum VAS score of 8-10 and when patient demands for 
additional analgesics. Dexamethasone significantly prolonged the 
postoperative analgesic duration (mean 1028 minutes) which was 
significant than tramadol (453.17 minutes) (P <0.05).This helps to 
minimize the cost and provides patient comfort. 
 
6. Sebastien Robaux et al 2004
22
 designed a prospective, 
randomized, controlled and double-blind clinical trial to assess and 
evaluate the time of onset and quality of postoperative analgesia, and 
occurrence of adverse effects of tramadol in one-hundred patients 
scheduled for carpal tunnel release surgery. All patients received 
1.5% mepivacaine 40ml.The patients were randomly divided into 
four groups so that 17 patients received isotonic sodium chloride 
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(Group P), 22 patients received tramadol 40 mg (Group T40), other 
20 patients received tramadol 100 mg (Group T100) and remaining 
20 received tramadol 200 mg (Group T200).Onset and duration of 
sensory and motor blocks were not different among groups. The 
number of patients requesting analgesia in the postoperative period 
was significantly less in the 3 tramadol groups compared with the 
placebo group (P=0.02); this was also noted with the placebo and 
T40 groups compared with the T200 group. No statistical 
significance was demonstrated between the placebo and the T40 
group or the T100 group and the T200 group. Furthermore, there was 
a significant trend effect among groups applying the Cochran-
Armitage tendency test (P=0.003), suggesting a dose-dependent 
decrease for additional postoperative analgesia requirements when 
tramadol was added. Side effects did not differ among groups, 
although they were more frequently recorded in the T groups. Study 
suggests that tramadol added to 1.5% mepivacaine for brachial 
plexus block enhances in a dose-dependent manner the duration of 
analgesia with acceptable side effects. However, the safety of 
tramadol has to be investigated before allowing its use in clinical 
practice. 
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7. Olfa Kaabachi et al 2009
23
 conducted a prospective randomized 
study to evaluate the effect of varying doses of tramadol as an 
adjuvant to axillary block with lidocaine 1.5% (epinephrine 1/2, 
00,000). Three groups were allotted randomly, control group 
received 4ml saline, TL group received100mg tramadol and 2ml 
saline and TH group received 200mg tramadol along with lidocaine. 
The results showed that the addition of 200mg tramadol prolonged 
the analgesic duration with a delayed onset time. 
 
8. Stephan Kapral et al 1999
24
 studied in patients randomly 
assigned to receive either 40ml of 1% mepivacaine with 2ml of 
isotonic sodium chloride solution (Group A), 40 ml of 1% 
mepivacaine with 100mg tramadol or 40ml of 1% mepivacaine with 
2ml of isotonic sodium chloride and 100mg tramadol 
intramuscularly and evaluated that when tramadol 100mg added to 
1% mepivacaine prolongs the duration of blockade without any 
adverse effects in brachial plexus axillary block. Tramadol may be a 
useful alternative to epinephrine and clonidine as an adjuvant to local 
anaesthesia for axillary block. 
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9. F. Alemanno et al 2012
25
 studied in 120 patients allocated in 3 
groups. Group P received 0.4ml/kg of 0.5% levobupivacaine plus 
isotonic sodium chloride and isotonic sodium chloride 
intramuscularly. Group TPN ( perineural tramadol) received 0.4ml/kg 
of 0.5% levobupivacaine plus 1.5mg/kg tramadol perineurally and 
isotonic sodium chloride intramuscularly and last Group TIM received 
0.4ml/kg of 0.5% levobupivacaine plus isotonic sodium chloride 
perineurally and 1.5mg/kg tramadol intramuscularly and concluded 
that the  TPN Group  Tramadol and 0.5% levobupivacaine after single 
-  shot interscalene block in patients undergoing shoulder 
arthropalsty extends the duration of postoperative analgesia without 
significant side effects. 
 
10. Ravi Madhusudhana et al 2011
26
 studied and concluded that 
there are significant beneficial effects on duration of sensory, motor 
blockade and VAS scores when tramadol 50mg and fentanyl 50mcg   
added to local anaesthetics 0.75%  ropivacaine in supraclavicular 
brachial plexus block. 
 
11. W. Kunapis et al 2010
27
 studied and concluded that adding 
tramadol 2mg/kg to bupivacaine 1.3mg/kg in brachial plexus block 
for orthopedic procedures in dogs provides faster onset and highly 
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effective quality and prolonged duration of analgesia with superior 
pain relief and less requirement of isoflurane to maintain anaesthesia.
   
Tramadol in other regional anaesthetic procedures: 
12. Ahsan K. Siddiqui et al 2008
28
 studied and confirmed that 
tramadol 100mg is an effective dose that shortens the sensory block 
onset, improves tourniquet tolerance and also reduces the 
intraoperative analgesia consumption when added as adjuvant to 
intravenous regional anaesthesia with lignocaine. 
 
13. Ahed Zeidan et al 2008
29
 studied and concluded that 
intraarticular  admixture of 100mg Tramadol hydrochloride with 
0.25% Bupivacaine   provided  longer duration of analgesia 
postoperatively with significant lower requirement of rescue 
analgesia and not associated with any adverse effects when 
compared to bupivacaine group and tramadol group. This was also 
associated with earlier recovery of unassisted ambulation and home 
discharge. 
 
14. Shrestha BR et al 2005
30
   studied and concluded that when 
tramadol 2mg/kg used as an admixture with Local Anaesthetics 
bupivacaine(1mg/kg) and lignocaine (<2mg/kg) can produce an 
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average  duration of postoperative analgesia of 18 hours following 
circumcision in the children. 
 
15. Yu Chuan Tsai et al 2001
31
 studied direct tramadol application 
on sciatic nerve inhibits spinal somatosensory evoke potentials in 
rats and concluded that direct application of tramadol on the sciatic 
nerve inhibits SSEP in a dose dependent and reversible manner that 
is not affected by naloxone and their data suggest that tramadol 
exerts a local anaesthetic type effect on peripheral nerves. 
 
16. E Kargi et al 2008
32
 studied tramadol as a local anaesthetic in 
tendon repair surgery of the hand and concluded that 5% tramadol 
plus adrenaline had local anaesthetic effects similar to those of 
lidocaine plus adrenaline when used as infiltration anaesthesia during 
the surgical repair of injured tendons of the hand. Furthermore 
treatment with tramadol plus adrenaline was not associated with any 
local side effects and there was no requirement for additional 
analgesia during the first 24hour post operation. 
 
17. Shrestha SK et al 2010
33
 studied and concluded that caudal 
administration of 1mg/kg tramadol along with 0.5ml/kg of 0.25% 
bupivacaine improves the quality and prolongs the duration of 
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postoperative analgesia in children undergoing infra-umbilical 
surgeries, without any adverse effects. 
 
18. J Balavenkatasubramnian et al 2008
34
 in his study continuous 
peripheral nerve block: the future of Regional Anaesthesia? said 
peripheral opioids – opioid agents are known to exert their effects 
peripherally. Adding small doses of opioids to local anaesthetic 
solution for peripheral block have resulted in improvement in the 
onset time, quality and duration of nerve block. Tramadol has a local 
anaesthetic effect on peripheral nerves and could provide potentially 
a synergestic effect in continuous infusion as an additive to local 
anaesthetic agent. 
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10. MATERIALS AND METHODS 
 
 This study was conducted at Thanjavur Medical College and 
Hospital, Thanjavur in orthopaedic and plastic surgery theatres. 
 
A prospective double – blinded randomized control study 
conducted on 60 patients of ASA grade I or II of either sex and age 
more than 19 years undergoing upper limb surgery under 
supraclavicular brachial plexus block performed by subclavian 
perivascular approach with nerve stimulator were included. 
 
 The study was started after receiving institutional ethical 
committee approval and informed written consent from the patients 
and they were randomly divided into two groups namely- 
 
Group B: 30 patients received 38ml of 0.25 % bupivacaine +                     
                2ml normal saline 
 Group BT: 30 patients received 38ml of 0.25% bupivacaine 
+  
                2ml tramadol (2mg/kg). 
Care was taken so that the toxic doses of the local anesthetics were 
not exceeded according to the weight of the patients. 
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Inclusion criteria 
 
The following criteria were taken for including the patients in 
this study. 
• ASA Status I and II 
• Age between 19 and 72 years 
• Weight ≥ 50 kg 
• Patients undergoing surgeries in distal end of arm, forearm and hand 
 
Exclusion criteria 
• Patient refusal 
• Local infections at the site of puncture for block / Sepsis 
• Known allergy for the drugs to be studied. 
• Coagulation abnormalities 
• H/o significant systemic disorders 
• Alcohol/drug abuse 
• Pregnancy/lactating women 
• Chronic analgesic therapy (other than NSAIDS) 
• Peripheral neuropathy 
• Very obese 
• Not fulfilling inclusion criteria 
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Investigations Required 
• Hb%, TC, DC, BT, CT 
• Urine routine 
• Random Blood sugar 
• Serum Urea and Serum Creatinine 
• Chest X-ray, ECG 
• HIV 
 
MATERIALS 
1. Sterile tray for regional blocks 
2. Drugs for the block 
0.5% bupivacaine 
Inj. tramadol 
Normal saline 
Distilled water 
2% lignocaine 
3. Nerve stimulator with insulated needle 
4. Equipments and drugs for resuscitation and conversion to general    
   anaesthesia in the case of block failure. 
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Methods 
Pre Operative preparation                                            
    Patients were pre-operatively assessed and the procedure was 
explained to the patient. Written informed consent was obtained. 
They were assessed with particular attention to any 
contraindications. 
 
Postoperative assessment of pain was done using Visual 
Analogue Scale (VAS) .Patient was explained  pre operatively about 
the visual analogue scale as 0 – No pain and 10 the worst possible 
pain and was asked the score in visual analogue scale.  
 
Pre medication 
Tab. Ranitidine 150mg 2 hours before surgery with sips of water. 
 
Conduct of anaesthesia  
On arrival of the patient in the operating room, monitors like 
pulse oximeter, non invasive blood pressure and ECG were 
connected and baseline values were recorded. An 18 G intravenous 
access was obtained in the opposite arm. 
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40ml prepared solution for Brachial plexus block 
Supraclavicular approach by the subclavian perivascular technique 
with nerve locator done. 
 
After evaluation of blocks patients were sedated with Inj. 
midazolam 0.05mg/kg slow iv along with inj. metaclopramide 10mg 
iv. Patients were given supplemental O2 through face mask and 
intravenous fluids throughout the procedure and they were properly 
screened from the surgical field. 
 
Parameters observed 
1. Onset of sensory blockade: - evaluation has done every minute 
after the performance of the block by Hollman’s scale. 
1. normal sensation of pin prick 
2. pinprick felt as sharp but weaker compared with the same area in 
the other limb. 
3. pinprick recognized as touch with blunt object. 
4. no perception of pin prick. 
Onset of blockade was taken as abolishment of pin prick pain 
(Hollman’s ≥ 3) over the distribution of ulnar and median nerve. 
2. Onset of motor blockade : Onset of motor blockade was assessed 
every minute after the block using Bromage three point score 
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0 – normal motor function with full flexion and extension of  
      elbow, wrist and fingers. 
1- decreased motor strength with ability to move fingers and 
/or wrist only 
2-  complete motor blockade with inability to move fingers 
Attaining a score of 2 was considered as the onset of motor block. 
3. Duration of surgery: Time taken by the surgeon to do the 
surgical procedure. 
4. Duration of motor blockade: When (2) in the three point score 
changes to (1) the motor blockade is said to reverse. The duration of 
motor block is noted from the time from score (2) to scale (0). 
 The pain was assessed using visual analogue scale having 
10cm length from 0 to 10.0 – no pain; 10-worst pain. The patient  
were observed every 30 minutes after the surgery is over till the 
motor block reverses and there after hourly for 6 hours, 2 hourly for 
next 6 hours and then 24 hours. 
5. Duration of Sensory block: Taken from the time of onset of 
block to first complaint of pain sensation (vas score 1) 
6. Duration of analgesia: Taken from the time of the onset of block 
to appearance of pain requiring analgesia (vas score more than 4). 
75 
 
7. Rescue Analgesia: Time at which VAS score is greater than 4 is 
noted and patient was given rescue analgesic in the form of inj. 
Diclofenac sodium intragluteally in the dose of 1.5mg/kg along with 
inj. ranitidine 50mg given intravenously. Numbers of rescue 
analgesics in 24hours of postoperative period were recorded. 
 
8. Vital parameters: 
Pulse rate, blood pressure, saturation were monitored every 
5min for first 30min and thereafter 15min till the end of surgery. 
    
9. Perioperative complications and side effects were observed for 
24hours 
 Respiratory Depression 
 Pneumothorax 
 Neurological sequale 
Nausea 
Vomiting 
Hypotension 
Bradycardia 
Sedation 
Shivering 
Dry mouth 
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Arrhythmia 
 Local anaesthetic toxicity 
Pneumothorax. 
10. Block failure: Failure of the block to be established even after 30 
minutes was taken as block failure.Patients in which the block was 
unsuccessful due to total failure or missed dermatomes which needed 
general anesthesia or intravenous supplementation were excluded 
from the study. 
11.  All the data were subjected to statistical analysis. 
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11. OBSERVATIONS AND RESULTS 
 
 The information collected in our study Group B and Group 
BT were recorded in a Master Chart. Data analysis was done with the 
help of computer using SPSS. For statistical analysis students t test 
was used for comparison between the groups. Using this range, 
frequencies, percentages, means, standard deviations, chi square and 
‘p’ values were calculated. A ‘p’ value less than 0.05 was considered 
statistically significant. 
 
Demographic profile of the patients:  
Table 1: 
 
The above table shows that the average age was 38.87 ± 
13.544 years in group B and 36.40 + 11.440 years in group BT. 
Youngest patient in our study group was 19 yrs and oldest was 72 
years. The average weights of the patients were 66.70 + 5.914 kgs in  
Sl. 
No. 
Demographic 
profile 
Control group 
(B) 
Tramadol Group 
(BT) 
1 No. of patients 30 30 
2 Average age (years) 38.87 + 13.544 36.40 + 11.440 
3 Weight (in Kgs) 66.70 + 5.914 66.90 + 5.026 
4 
Gender ratio 
(Male : Female) 
17:13 24:6 
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GRAPH 1:  
MEAN AGE OF THE PATIENT 
 
 
GRAPH 2:  
SEX DISTRIBUTION OF PATIENTS 
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group B and 66.90 + 5.026 kgs in group BT respectively. Majority of 
the patients in both groups were males. There was no significant 
difference in age, weight and sex distribution. 
 
Table: 2   Mean Age of the patients (years) 
Sl.no Age 
Group Statistical 
inference B (n=30) BT (n=30) 
1 Below 30yrs 
11 
(36.7%) 
11 
(36.7%) 
X
2
=3.651 
Df=3 
.302>0.05 
Not Significant 
2 31 to 40yrs 8 (26.7%) 
11 
(36.7%) 
3 41 to 50yrs 7 (23.3%) 2 (6.7%) 
4 
51yrs & 
above 
4 (13.3%) 6 (20%) 
 
Table : 3    Sex distribution  
Sex Group R Group RC 
 No % No % 
Male 17 56.7 24 80 
Female 13 43.3 6 20 
Total 30 100 30 100 
‘p’ 0.0959>0.05 Not significant 
 
Table : 4                          Mean Weight 
Sl. no Weight Mean S.D Statistical inference 
1 B (n=30) 66.70 5.914 T= -.141 
.888>0.05 
Not Significant 2 BT (n=30) 66.90 5.026 
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GRAPH 3:  
MEAN WEIGHT OF THE PATIENTS 
 
 
GRAPH 4: 
DURATION OF SURGERY 
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GRAPH 5:  
ASA STATUS 
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Surgical profile of the patients: 
Table : 5 
 
Table 6:                                      ASA Status 
ASA Status 
Group R Group R C 
No % No % 
I 25 83.3 25 83.3 
II 5 16.7 5 16.7 
Total 30 100 30 100 
‘p’ 2 >0.05 not significant 
 
Table 7:                 Duration of surgery in hours 
Duration of surgery in hours Mean  S.D Statistical inference  
B (n=30) 1.89 .484 T=1.089 
.281>0.05 
Not Significant  BT (n=30) 1.77 .388 
 
ASA Status, type and duration of surgery were similar in both 
groups. The mean duration of surgery was 1.89 + 0.484 hours in 
group B compared to 1.77 + 0.388 hours in BT group. There was no 
clinical or statistical significance. 
 
              Surgical Profile 
1 ASA Status( ׀ : ׀׀) 25:5 25:5 
2 
Duration of surgery 
 (in hours) 
1.89 + 0.484 1.77 + 0.388 
3 
Type of operations 
(orthopaedic : Plastic surgeries) 
(16:14)  (19:11) 
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2. Onset of sensory block between study groups: 
The mean time for onset of sensory block in Group B was 
17.20 ± 2.140  and in Group BT was10.07 ± 1.837 .the statistical 
analysis by students ‘t’ test showed that the time for onset of sensory 
block in group BT was significantly faster when compared to Group 
B (p <0.05)  as shown in  Table 8 and Graph 6. 
Table: 8                    
onset of Sensory block in 
Minutes 
Mean  S.D Statistical 
inference  
B (n=30) 17.20 2.140 T=13.854 
.000<0.05 
Significant  
BT (n=30) 10.07 1.837 
 
Graph 6:                  
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3. Onset of motor block between study groups: 
The mean time for onset of motor  block in Group B was 9.10 
± 1.373minutes  and in Group BT was5.83 ± 1.053minutes  as shown 
in table 9 and Graph 7.The statistical analysis by students ‘t’ test 
showed that the time for onset of motor block in group BT was 
significantly faster when compared to Group B ( p <0.05)   
Table: 9                  
Onset of motor block in 
minutes 
Mean S.D Statistical 
inference 
B (n=30) 9.10 1.373 T=10.338 
.000<0.05 
Significant BT (n=30) 5.83 1.053 
 
Graph: 7  
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4. Duration of sensory block in hours: 
The duration of sensory blockade in Group B was 3.18 ± 0.524 
hours and in Group BT, was 5.88 ± 0.669 hours as shown table 10, 
Graph 9.The statistical analysis by students ‘t’ test showed that the 
time for duration of sensory block in group BT was significantly 
longer when compared to Group B (.000<0.05) 
Table: 10                  
Duration of sensory block 
in hours. 
Mean  S.D Statistical 
inference  
B (n=30) 3.18 .524 T=-17.392 
.000<0.05 
Significant  BT (n=30) 5.88 .669 
 
Graph:9 
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5. Duration of motor block in hours: 
The duration of motor blockade in Group B was 2.34 ± 0.362 
hours and in Group BT, was 4.65 ± 0.654 hours as shown table 
11,graph 10.The statistical analysis by students‘t’ test showed that 
the time for duration of  motor blockade in group BT was 
significantly longer when compared to Group B ( P < 0.05). 
Table: 11                
Duration of motor block 
in hours. 
Mean  S.D Statistical 
inference  
B (n=30) 2.34 .362 T=-16.916 
.000<0.05 
Significant  BT (n=30) 4.65 .654 
 
Graph: 10 
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GRAPH 8: 
MEAN ONSET OF MOTOR AND SENSORY BLOCK IN STUDY 
GROUPS 
 
GRAPH 11: 
MEAN DURATION OF SENSORY AND MOTOR BLOCK IN 
STUDY GROUPS 
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6.Duration of analgesia in hours: 
The duration of analgesia in Group B was 3.42 ± 0.283 hours 
and in Group BT, was 7.06 ± 2.894 hours as shown table 12, graph 
12.The statistical analysis by students ‘t’ test showed that the time 
for duration of analgesia in group BT was significantly longer when 
compared to Group B (p < 0.05). 
Table: 12              
Duration of analgesia in 
hours 
Mean  S.D Statistical 
inference  
B (n=30) 3.42 .283 T=-6.849 
.000<0.05 
Significant  BT (n=30) 7.06 2.894 
 
Graph: 12 
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7. Number of rescue analgesia in 24hours Post operative period: 
In Group B patients required 2.43± 0.568 rescue analgesic 
dosage and in group BT patients required only 1.13±  0.434 rescue 
analgesic doses in postoperative 24hours as shown in table 13 and 
graph 13.This difference in number of rescue analgesic doses 
required by patients of both groups is statistically significant (p < 
0.05). 
Table: 13         
Number  of rescue analgesics  in 
24hours Post operative period 
Mean S.D 
Statistical 
inference 
B (n=30) 2.43 .568 T=9.956 
.000<0.05 
Significant BT (n=30) 1.13 .434 
 
Graph: 13 
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8. Hemodynamic variables:  Pulse rate ,systolic blood pressure, 
diastolic blood pressure and oxygen saturation were recorded at 
0min, 2 mins,5mins,10mins, 15mins,30 mins,1 hour, 2 hours, 3 
hours,6 hours,12 hours and 24 hours.  
 
 
Pulse rate (beats/min) 
There was no significant difference in pulse rate between the 
two groups as shown in table 14 and graph 14(p >0.05). None of the 
patients in both group developed bradycardia. Table: 14. 
 
Pulse Study group Mean S.D Statistical inference 
0minutes B (n=30) 83.73 12.868 T=.152,0.880>0.05 
Not Significant  BT (n=30) 83.23 12.607 
2minutes B (n=30) 82.10 13.116 T=.000, 1.000>0.05 
Not Significant  BT (n=30) 82.10 12.115 
5minutes B (n=30) 80.53 12.294 T=.129, 0.898>0.05 
Not Significant  BT (n=30) 80.13 11.685 
10minutes B (n=30) 79.90 12.307 T=.217, 0.829>0.05 
Not Significant  BT (n=30) 79.23 11.482 
15minutes B (n=30) 79.20 11.883 T=.546, 0.587>0.05 
Not Significant  BT (n=30) 77.57 11.288 
30minutes B (n=30) 78.60 11.254 T=.035, 0.972>0.05 
Not Significant  BT (n=30) 78.50 10.919 
1hour B (n=30) 78.00 11.151 T=.368, 0.714>0.05 
Not Significant  BT (n=30) 76.97 10.604 
2hour B (n=30) 77.33 11.056 T=.312, 0.756>0.05 
Not Significant  BT (n=30) 76.47 10.421 
3hours B (n=30) 75.27 10.225 T=-.203, 0.839>0.05 
Not Significant  BT (n=30) 75.80 10.077 
6hours B (n=30) 79.47 11.301 T=.289, 0.774>0.05 
Not Significant  BT (n=30) 78.70 9.136 
12hours B (n=30) 79.33 10.337 T=.027, 0.978>0.05 
Not Significant  BT (n=30) 79.27 8.662 
24hours B (n=30) 80.80 10.317 T=.470, 0.640>0.05 
Not Significant  BT (n=30) 79.60 9.420 
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GRAPH 14: 
CHANGES IN PULSE RATE (beats/minute) 
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Systolic blood pressure (mmHg)  
The mean systolic blood pressure between the two groups as 
shown in table 15 and graph 15 was comparable (p > 0.05).None of 
the patients in both group developed hypotension.Table:15 
Time of Assessment Groups Mean S.D Statistical inference 
0 mins B (n=30) 122.67 9.444 T=-.647 
.520>0.05 
Not Significant 
 BT (n=30) 124.20 8.919 
2 mins B (n=30) 124.00 8.550 T=-.089 
.930>0.05 
Not Significant 
 BT (n=30) 124.20 8.919 
5 mins B (n=30) 123.87 8.629 T=-.030 
.977>0.05 
Not Significant 
 BT (n=30) 123.93 8.843 
10 mins B (n=30) 123.80 8.588 T=.569 
.571>0.05 
Not Significant 
 BT (n=30) 122.53 8.645 
15 mins B (n=30) 122.80 9.182 T=-.029 
.977>0.05 
Not Significant 
 BT (n=30) 122.87 8.593 
30 mins B (n=30) 121.80 8.684 T=-.285 
.777>0.05 
Not Significant 
 BT (n=30) 122.47 9.449 
1 hr B (n=30) 121.27 8.686 T=-.908 
.367>0.05 
Not Significant 
 BT (n=30) 123.33 8.934 
2 hr B (n=30) 121.20 8.704 T=-2.002 
.052>0.05 
Not Significant 
 BT (n=30) 125.53 8.046 
3 hr B (n=30) 121.07 8.610 T=-2.431 
.081>0.05 
Not Significant 
 BT (n=30) 126.20 7.725 
6hr B (n=30) 120.20 7.618 T=-1.152 
.254>0.05 
Not Significant 
 BT (n=30) 122.40 7.171 
12hr B (n=30) 119.73 7.196 T=-1.175 
.245>0.05 
Not Significant 
 BT (n=30) 121.87 6.867 
24hr B (n=30) 119.67 7.184 T=-1.171 
.246>0.05 
Not Significant 
 BT (n=30) 121.73 6.470 
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GRAPH 15:  
CHANGES IN MEAN SYSTOLIC BLOOD PRESSURE 
(mmHg) 
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Diastolic blood pressure (mmHg) 
There was no significant difference in Diastolic Blood 
pressure between the two groups as shown in table 16 and graph 16 ( 
p > 0.05) 
Table: 16 
Time of Assessment Groups Mean S.D Statistical inference 
0 mins B (n=30) 75.33 6.288 T=-.182 
.856>0.05 
Not Significant 
 BT (n=30) 75.60 4.994 
2 mins B (n=30) 75.33 6.288 T=-.182 
.856>0.05 
Not Significant 
 BT (n=30) 75.60 4.994 
5 mins B (n=30) 75.33 6.288 T=-.137 
.892>0.05 
Not Significant 
 BT (n=30) 75.53 4.946 
10 mins B (n=30) 74.87 5.794 T=-.340 
.735>0.05 
Not Significant 
 BT (n=30) 75.33 4.795 
15 mins B (n=30) 74.60 5.537 T=.490 
.626>0.05 
Not Significant 
 BT (n=30) 73.93 4.996 
30 mins B (n=30) 73.87 5.144 T=.674 
.503>0.05 
Not Significant 
 BT (n=30) 73.00 4.807 
1 hr B (n=30) 73.33 5.101 T=.899 
.372>0.05 
Not Significant 
 BT (n=30) 72.20 4.649 
2 hrs B (n=30) 72.93 4.891 T=1.142 
.258>0.05 
Not Significant 
 BT (n=30) 71.53 4.599 
3 hrs B (n=30) 72.73 4.968 T=1.381 
.172>0.05 
Not Significant 
 BT (n=30) 71.00 4.749 
6 hrs B (n=30) 75.20 4.944 T=.211 
.834>0.05 
Not Significant 
 BT (n=30) 74.93 4.863 
12 hrs B (n=30) 74.87 5.722 T=-.288 
.775>0.05 
Not Significant 
 BT (n=30) 75.27 5.024 
24 hrs B (n=30) 75.80 5.616 T=-.149 
.882>0.05 
Not Significant 
 BT (n=30) 76.00 4.727 
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GRAPH 16:  
CHANGES IN MEAN DIASTOLIC BLOOD 
PRESSURE(mmHg) 
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SpO2: 
 The statistical analysis by students ’t’ test showed that there 
was no significant difference in oxygen saturation between the two 
groups as shown in table 17  and graph 17 (p >0.05) 
Table: 17 
Time of Assessment Groups Mean S.D Statistical inference 
0 mins B (n=30) 99.73 .521 T=.484 
.630>0.05 
Not Significant 
 BT (n=30) 99.67 .547 
2 mins B (n=30) 99.73 .521 T=.484 
.630>0.05 
Not Significant 
 BT (n=30) 99.67 .547 
5 mins B (n=30) 99.70 .535 T=.239 
.812>0.05 
Not Significant 
 BT (n=30) 99.67 .547 
10 mins B (n=30) 99.37 .556 T=-.209 
.835>0.05 
Not Significant 
 BT (n=30) 99.40 .675 
15 mins B (n=30) 99.30 .596 T=1.706 
.093>0.05 
Not Significant 
 BT (n=30) 99.03 .615 
30 mins B (n=30) 99.20 .610 T=1.257 
.082>0.05 
Not Significant 
 BT (n=30) 98.83 .648 
1 hour B (n=30) 99.03 .615 T=1.227 
.225>0.05 
Not Significant 
 BT (n=30) 98.83 .648 
2 hours B (n=30) 99.03 .669 T=1.412 
.091>0.05 
Not Significant 
 BT (n=30) 98.63 .615 
3 hours B (n=30) 99.10 .548 T=1.288 
.203>0.05 
Not Significant 
 BT (n=30) 98.93 .450 
6 hours B (n=30) 99.10 .548 T=1.288 
.203>0.05 
Not Significant 
 BT (n=30) 98.93 .450 
12 hours B (n=30) 99.03 .669 T=1.412 
.091>0.05 
Not Significant 
 BT (n=30) 98.63 .615 
24 hours B (n=30) 99.30 .596 T=1.904 
.051>0.05 
Not Significant 
 BT (n=30) 98.83 .648 
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GRAPH 17:  
OXYGEN SATURATION 
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 Comparison of side effects:  
None of the patients in both the groups developed any 
complications. 
Table : 18 
Side effects Group B Group BT 
Bradycardia Nil Nil 
Hypotension Nil Nil 
Nausea Nil Nil 
Vomiting Nil nil 
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12. DISCUSSION 
 
The supraclavicular brachial plexus approach is a very popular 
mode of anaesthesia, in which a small volume of solution can be 
delivered at a point where three trunks are compactly arranged, 
resulting in rapid onset of reliable blockade of the brachial plexus, to 
provide excellent anaesthesia for elbow, forearm and hand surgery 
and also provides good postoperative analgesia of short duration, 
even when a long acting local anaesthetic like bupivacaine is used 
alone. The nerve stimulator can be used to aid the location of the 
brachial plexus and plain bupivacaine used by this method has been 
claimed to produce the block as long as 3 – 8 hours. Practically the 
same result couldnot be produced in series of study with sole 
bupivacaine. To extend the analgesia beyond the operation rooms, 
various local anaesthetic action like continuous infusion of local 
anaesthetic via in dwelling catheters, use of different additives in 
local anaesthetics like narcotics, opioids, calcium channel blockers 
and benzodiazepine have been added to the local anaesthetics and 
their effect on the quality of block studied. A variety of opioids have 
been studied for brachial plexus blockade including tramadol 
hydrochloride.  
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Tramadol is known to produce antinociception and to enhance 
the effect of local anaesthetic. Tramadol produces this effect by its 
dual mechanism of action. Firstly it stimulates μ receptor and to 
lesser extent δ and κ - opioid receptors. Secondly it activates spinal 
inhibition of pain by decreasing the reuptake of norepinephrine and 
serotonin (non opioid mechanism) in peripheral nerve blocks. 
Several studies have demonstrated the advantage of using tramadol 
hydrochloride through various routes for analgesia. 
 
Hence an attempt has been made to assess the efficacy of 
tramadol (2mg/kg) as an adjuvant to bupivacaine (0.25%) in brachial 
plexus block (supraclavicular approach) in terms of onset time, 
duration of analgesia, hemodynamic variables and rescue analgesic 
requirements in the first 24 hours. 
 
We used nerve stimulator technique which has the advantage 
of minimizing neuropathy by avoiding actual physical contact with a 
nerve compare to paresthesia technique. When an electrical current is 
used to stimulate a nerve, at lower current the motor fibres 
depolarizes than the sensory fibers leading to a painless visible 
muscle contraction without eliciting a paresthesia. The high success 
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rate and absence of complications in performing the subclavian 
perivascular technique of brachial plexus block by nerve stimulator 
indicate that our technique is safe and effective also said by Carlo D. 
Franco et al
35
 in his study. 
 
A volume of 40ml of local anaesthetic agent was taken as this 
volume was associated with a more complete spread for brachial 
plexus block as found by Winnie and colleagues
36
.  
 
The particular dose of Tramadol 2mg/kg (100mg) was selected 
after previous studies like Kapral et al
24
, Antonucci et al
19
, Renu 
Wakhlo et al
18
, Geze et al
20
 and Siddiqui AS et al
28
 used the same 
dosage in peripheral nerve block without any significant adverse 
effects. 
 
A total of 60 patients within the age group of 19-72 were in 
included in the study, 30 in each Group B and Group BT. 
 
Onset of Action: 
In our study we found that the onset of sensory and motor 
block were significantly faster in patients who received a 
combination of tramadol and bupivacaine. Onset of motor block 
(group BT, 5.83 ± 1.053 min; group B, 9.10 ± 1.373 min).Onset of 
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sensory block (group BT 10.07 ± 1.837 min; group B 17.20 ± 2.140 
min).  
 
This could be due to a local direct action of Tramadol and its 
synergistic action with that of local anaesthetics. The onset of motor 
block was significantly faster than the onset of sensory block in both 
groups, this can be explained by ‘Core and Mantle’ concept of 
Winnie et al 1977
2
, He observed and attributed this to the 
somatotrophic arrangement of fibres in a nerve bundle at the level of 
the trunks in which motor fibres are located more peripherally form 
the mantle and are blocked earlier than the sensory fibres at the core. 
Hence a local anaesthetic injected perineurally will begin to block 
the motor fibres before it arrives at the centrally located sensory 
fibres. 
 
Duration of Motor and Sensory Block: 
In our study mean duration of motor block was prolonged 
when tramadol was added to bupivacaine. (Group BT, 4.65 ± 0.654 
hours; Group B, 2.34 ± 0.362 hours). In our study, the mean duration 
of sensory block was significantly higher (P < 0.05) in group BT 
than in group B. (Group BT, 5.88 ± 0.669 hours; Group B, 3.18 ± 
0.524 hours).  
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Our results showed that sensory block tended to last longer as 
compared to motor block which agrees with the observation by de 
Jong et al
37
. These authors explained that large fibres require a higher 
concentration of local anaesthetic than small fibres. The minimal 
effective concentration of local anaesthetic for large (motor) fibres is 
greater than for small (sensory) fibres.Thus, motor function returns 
before pain perception and duration of motor block is shorter than 
the sensory block.  
 
Duration of Analgesia: 
In our study duration of analgesia (from onset of blockade to 
requirement of first supplement analgesic) was significantly higher 
in Tramadol Group BT (7.06 ± 2.894) compared to Group B (3.42 ± 
0.283).  
These results are comparable with the study of Suman 
Chattopadhyay et al
17
. 
 
Tramadol as analgesic adjuvants:  
Various studies of Tramadol used in peripheral nerve block 
showed that Tramadol with Bupivacaine improves analgesic 
characteristics compared to Bupivacaine alone when administered 
for various peripheral nerve blocks. 
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Renu Wakhol et al
18
 showed addition of (100 mg) 2 mg/kg of 
Tramadol to local anesthetic was found to be good agent for 
hastening the onset and prolonging sensory and motor block. 
 
Sebastein Robaux et al
22
 found that addition of tramadol to 
local anaesthetic agents improved the onset and duration of motor 
blockade. Antonucci S et al
19
 found that Tramadol 100mg useful 
alternative, as adjuvant in peripheral block with lower incidence of 
side effects. 
 
W. Kunapis et al
27
 showed that adding Tramadol to 
Bupivacaine for brachial plexus block provides faster onset and 
longer duration of analgesia, improves the quality of analgesia. 
Siddiqui AK et al
28
 studied addition of Tramadol 1mg/kg (50 mg) 
and (100mg) 2 mg/kg. Suggested that Tramadol 100mg is beneficial 
additive to lignocaine for IVRA since it shortened the onset of 
sensory block, enhanced the tourniquet tolerance and improved the 
perioperative analgesia.  
All the studies are comparable with our results. 
Tramadol has a local anaesthetic effect on peripheral nerves as 
this could provide potentially a synergistic effect in continuous 
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infusion as an additive to local anaesthetic agent has been studied by 
J.Balavenkatasubramanian
34
. 
 
Rescue Analgesia: 
In our study, the number of patients who required rescue 
analgesia was also significantly lower in patients in Group BT. 
Similar observation was made in the above mentioned study by 
Suman Chattopadhyay et al
17
. The prolonged analgesia in Group BT 
could be due to local anaesthetic type effect of Tramadol on 
peripheral nerves as demonstrated by Yu-Chan Tsai et al
31
.  
 
Tramadol, an analgesic with peripheral effects similar to 
clonidine, moderately increases sensory block duration when 
compared with placebo or systemic control as mentioned in study by 
Joseph M. Neal et al
38
. Adding small doses of opioids to local 
anaesthetic solutions for peripheral blocks have resulted in 
improvement in the onset time, quality and duration of nerve block. 
 
Side effects:  
No significant side effects like respiratory depression, 
pneumothorax, signs and symptoms of local anaesthetic toxcity or 
neurological sequale were observed in any of the two groups. The 
lack of significant side effects like respiratory depression and 
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sedation make Tramadol as an adjuvant for supraclavicular brachial 
plexus block. 
 
Haemodynamic parameters 
 In this study there was no significant change in the 
haemodynamic parameters between the groups. This was consistent 
with the observation by Suman Chattopadhyay et al
17
. 
 
In conclusion, Tramadol 100mg (2 mg/kg) when added to 
38mL of Bupivacaine 0.25% for supraclavicular brachial plexus 
block speeds the onset of sensory and motor blocks (P < 0.05). The 
combination produces improved analgesia, resulting in a prolonged 
effect and reduced requirements for rescue analgesics. 
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13. SUMMARY 
 
We conducted this study at Thanjavur Medical College and 
Hospital in 60 patients of both sex in age group of 19 to 72 years 
belonging to ASA ׀ and ׀׀ and their weight ranging in between 55 to 
80years posted for various upper limb surgeries under subclavian 
perivascular approach of brachial plexus block with nerve locator. 
 
 
The patients in group B received 38ml of 0.25% Bupivacaine 
and 2 ml Normal saline. In group BT received 38ml of 0.25% 
Bupivacaine and 2ml (2mg/kg) Tramadol. 
 
 
Parameters observed were time of onset of sensory block and 
motor block, duration of motor blockade, and sensory blockade, 
duration of analgesia, sedation score and side effects. 
 
This study shows that 
Addition of tramadol to bupivacaine, when compared to 
bupivacaine alone, shows  
1.  Earlier the onset of motor and sensory  blockade  
2.  increases the duration of motor and sensory blockade 
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3.  significantly prolongs the duration of analgesia 
4. Requirement of rescue analgesic in postoperative period 24 hours is 
less 
5. Does not cause significant haemodynamic changes, respiratory 
depression, sedation or other adverse effects. 
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14. CONCLUSION 
 
From our study we conclude that the addition of the tramadol 
2mg/kg to 0.25% bupivacaine solution in brachial plexus block 
shows early onset of sensory and motor blockade and prolongs the 
duration of analgesia when compared to Bupivacaine alone. There 
are no significant side effects like respiratory depression and 
sedation. Hence tramadol may be considered as a useful adjuvant for 
bupivacaine when used for brachial plexus block. 
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PROFORMA 
A STUDY OF THE EFFICACY OF TRAMADOL AS AN ADJUVANT 
TO BUPIVACAINE IN BRACHIAL PLEXUS BLOCK 
Name:            I.P. No. : 
Age:          Department: 
Sex:          Date: 
Preoperative Observations: 
General Physical Examination: 
Pulse rate:         Blood Pressure: 
Respiratory rate:        Weight: 
Systemic Examination: 
C.V.S: 
R.S:         Others : 
Investigations: 
Hb%:      R.B.S:     ECG: 
Blood Urea:     S.Creatinine:    Urine routine: 
Preoperative Diagnosis: 
Proposed surgery: 
ASA Grade: 1 / 2 
STUDY PROTOCOL: 
Drug and Dosage Group:  B:   38ml of Bupivacaine 0.25% + 2ml NS  
                                             BT: 38ml of Bupivacaine 0.25% + 2ml Tramadol (2mg/kg) 
 
 
Observations: 
1) Time of Injection: 0 min 
2) Time of onset of sensory blockade: _____min 
3) Time of onset of motor blockade: _____min 
4) Quality of analgesia: Complete / Partial / Nil 
MONITORING: 
Time Pulse rate 
Per min 
Systolic BP 
mmHg 
Diastolic BP 
mmHg 
Spo2 % 
0     
2     
5     
10     
15     
30     
1hr     
2hr     
3hr     
6hr     
12hr     
24hr     
 
5) Duration of surgery: ________ mins, ________ hours 
6) Duration of sensory blockade: _____mins, ________ hours 
7) Duration of motor blockade: ______ mins,_________hours 
8) Duration of analgesia: ________ mins,__________hours 
9) No. of rescue analgesics in post-op 24 hours: _________ 
Untoward effects, if any: 
Supplementation, if any: 
GROUP B - BUPIVACAINE 
SL. No Age Sex 
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1 66 M 70  II  Dupuytr. Contrac.-Rt relese 16 8 3.6 2.8 3.5 1 nil 2 
2 48 M 73 I Nec. fascitis Rt arm -W Debd. 18 11 3.8 2.6 4 1.5 nil 2 
3 28 M 72 I Lt Radius #- ORIF 16 7 2.7 2.3 3.2 1.6 nil 3 
4 37 M 63 I Lt Olecranon #-ORIF 15 8 2.5 2 3.6 2 nil 2 
5 50 F 65 I Rt Thumb injury-Repair 20 10 3.4 2.2 3.4 1.5 nil 2 
6 72 M 65 II BB# Rt FA- ORIF 18 10 2.2 2 3.5 2 nil 2 
7 24 M 63 I Cut injury Lt hand- Repair 18 10 3.8 3 3.3 1.5 nil 3 
8 50 F 68 I Cut injury Lt hand- Repair 20 9 3.6 2.4 3 1.5 nil 2 
9 24 F 63 I Rt Radius head #-Excision 12 9 3 2 2.9 1.5 nil 3 
10 30 F 64 I Tendon injury R-Hand -repair 21 8 3 2.1 3.5 2.2 nil 2 
11 26 F 65 I PIP Jt. dislocation F3 K-wire FIX 17 8 2.5 2 3.5 1 nil 2 
12 27 M 66 I PBC-Lt hand-Release &SSG 14 9 3.3 2.4 3.5 2.5 nil 2 
13 35 F 60 I PBC LT Hand_Release@SSG 18 9 2.7 2 3 2.5 nil 3 
14 40 M 68 I Flap cover Rt FA-Flap thining 18 11 4.1 2.8 3.6 2 nil 1 
15 19 M 70 I RawareaLt Thumb_SSG 19 7 2.8 2.3 3.2 1.5 nil 3 
16 38 M 63 I Lt claw hand-TendonTransfer 20 8 3.2 2.5 3.5 3 nil 3 
17 37 M 76 I Cut Injury Rt hand-Repair 17 9 3.1 2.4 3.5 1.5 nil 2 
18 48 M 74 I BB#F Arm Lt_ORIF 16 10 2.8 2 3.4 1.6 nil 3 
19 34 M 76 I EXT TEN injuryLt hand_Repair 17 10 3 3.2 3.6 2 nil 3 
20 21 F 57 I Flex Ten InjuryRt FA-Repair 18 14 2.8 2 3 2 nil 3 
21 37 M 80 I Cut InjuryRt F2,3,4_Repair 16 8 4 2 3.5 2 nil 3 
22 38 M 62 I RawareaLt FArm_SSG 17 9 3 1.8 4 2.5 nil 2 
23 45 F 64 II PBC RT Hand_Release@SSG 15 10 3.1 2.2 3.2 2 nil 3 
24 28 F 66 I BB# Lt FA-ORIF 19 9 3.4 2.4 3.5 3 nil 2 
25 28 M 71 I #Radius head Lt_Excision 15 8 3.1 2.3 3.1 2 nil 2 
26 44 M 74 I Cut InjuryLt Hand_REPAIR 17 9 3.2 2.4 3.3 1.5 nil 3 
27 51 F 59 II #Olecranan Lt-ORIF 16 8 3.5 2.8 3.6 2 nil 2 
28 26 F 55 I #SOH Rt_ORIF 14 9 2.2 1.8 3.2 2 nil 2 
29 49 F 64 I Colles#Rt FA_ORIF 21 9 3.8 2.6 4 1.8 nil 3 
30 65 F 65 II #BB Lt FA_ORIF 18 9 4.1 2.8 3.5 2 nil 3 
 
GROUP-B - BUPIVACAINE PULSE RATE CHART (beats/mins) 
S.No GROUP 
0 
Mins. 
2 
Mins 
5Mins 
10 
Mins 
15 
Mins 
30 
Mins 
1hrs 2hrs 3hrs 6hrs 12hrs 24hrs  
1 B 90 94 93 92 90 85 85 84 84 90 85 88 
2 B 110 112 110 110 108 107 106 104 98 98 96 110 
3 B 78 75 74 74 72 72 72 72 70 80 75 78 
4 B 84 84 82 80 78 77 76 74 74 76 80 80 
5 B 120 116 108 106 104 101 100 99 98 100 100 96 
6 B 114 108 104 104 102 100 98 98 97 97 96 98 
7 B 82 78 76 77 77 77 77 76 76 78 77 77 
8 B 72 66 64 64 64 64 65 64 64 72 66 68 
9 B 84 80 78 76 76 76 75 74 72 78 80 80 
10 B 77 74 72 72 72 72 70 70 70 77 70 70 
11 B 73 68 66 66 66 66 66 65 64 64 65 68 
12 B 88 84 82 82 80 80 80 78 76 70 80 78 
13 B 78 72 72 71 70 70 72 70 70 70 74 75 
14 B 79 74 73 73 72 72 70 70 68 76 71 70 
15 B 77 75 74 74 74 74 74 72 70 70 74 78 
16 B 81 80 78 77 77 77 76 76 74 77 79 81 
17 B 86 87 85 84 84 84 82 82 80 85 85 80 
18 B 78 80 78 75 74 74 72 72 70 90 75 75 
19 B 72 70 68 65 65 64 64 66 64 65 74 69 
20 B 74 77 72 70 70 70 68 66 65 70 70 78 
21 B 76 74 75 76 75 75 75 73 71 71 71 78 
22 B 77 76 75 75 76 76 75 75 71 75 70 75 
23 B 71 70 70 69 68 69 66 67 65 66 71 77 
24 B 79 77 77 78 76 76 75 75 73 75 80 75 
25 B 69 71 71 70 70 69 71 70 68 70 70 74 
26 B 93 93 91 91 91 89 89 89 84 100 102 91 
27 B 89 88 88 88 88 87 87 87 83 81 82 94 
28 B 92 92 92 90 90 90 90 89 84 91 93 93 
29 B 70 69 70 70 70 69 68 67 65 71 74 74 
30 B 99 99 98 98 97 96 96 96 90 101 95 96 
 
 
                     GROUP B BUPIVACAINE SYSTOLIC BLOOD PRESSURE  CHART(mmHg) 
S.N
o 
0 
Mins 
2 
Min
s 
5Min
s 
10Min
s 
15Min
s 
30Min
s 
1hr 2hr 3hr 6hr 12hr 24hr 
1 110 120 118 118 110 110 110 110 110 110 110 110 
2 140 140 140 140 140 140 140 140 140 140 140 140 
3 130 130 130 130 130 130 128 128 128 130 130 130 
4 130 130 130 130 130 130 130 130 130 130 130 130 
5 130 130 130 130 130 128 128 128 128 120 120 120 
6 120 120 120 120 120 120 120 118 118 120 120 120 
7 120 120 120 120 120 120 120 120 120 120 120 120 
8 120 120 120 120 120 116 116 116 116 116 120 120 
9 120 130 130 130 120 120 118 118 118 120 120 120 
10 130 130 130 130 130 128 128 128 128 128 126 120 
11 130 130 130 130 130 128 128 128 128 128 120 120 
12 120 120 120 120 120 120 118 118 118 120 120 120 
13 120 120 120 120 120 120 118 118 118 118 120 120 
14 110 110 110 110 110 110 110 110 110 110 110 110 
15 130 130 130 130 130 130 128 128 126 120 120 120 
16 110 120 118 118 116 110 110 110 110 110 110 110 
17 110 110 110 110 110 110 110 110 110 110 110 110 
18 130 130 130 128 128 126 126 126 126 126 120 120 
19 120 120 120 120 120 120 118 118 118 120 118 120 
20 110 110 110 110 110 110 110 110 110 110 110 110 
21 130 130 130 130 130 128 128 128 128 120 120 120 
22 110 120 120 120 110 110 110 110 110 110 110 110 
23 120 120 120 120 120 120 120 120 120 120 120 120 
24 120 120 120 120 120 120 120 120 120 120 120 120 
25 140 140 140 140 140 136 136 136 136 130 128 130 
26 110 110 110 110 110 110 110 110 110 110 110 110 
27 120 120 120 120 120 120 118 118 118 120 120 120 
28 140 140 140 140 140 136 136 136 136 130 130 130 
29 120 120 120 120 120 120 118 118 118 120 120 120 
30 130 130 130 130 130 128 128 128 126 120 120 120 
 
 
GROUP B BUPIVACAINE DIASTOLIC BLOOD PRESSURES  CHART (mmHg)  
S.No 
0 
Mins 
2 
Mins 
5 
Mins 
10 
Mins 
15 
Mins 
30 
Mins 
1hr 2hrs 3hrs 6hr 12hr 24hr 
1 70 70 70 70 70 70 70 70 70 70 70 70 
2 80 80 80 78 78 76 76 76 76 78 76 80 
3 80 80 80 80 78 76 74 74 74 80 80 80 
4 80 80 80 80 80 80 80 80 80 78 72 80 
5 80 80 80 80 80 80 80 78 78 80 80 80 
6 80 80 80 80 80 80 80 78 78 80 78 78 
7 70 70 70 70 70 70 70 70 70 72 70 76 
8 80 80 80 78 76 74 74 74 74 76 80 80 
9 70 70 70 70 70 70 70 70 70 74 70 70 
10 80 80 80 76 76 74 74 72 72 76 76 80 
11 80 80 80 80 80 80 80 80 80 80 78 80 
12 80 80 80 80 80 80 80 80 80 78 80 80 
13 70 70 70 70 70 70 70 70 70 74 70 72 
14 60 60 60 60 60 60 60 60 60 64 62 62 
15 80 80 80 78 78 78 76 76 76 80 80 80 
16 80 80 80 80 78 78 76 76 76 80 80 80 
17 70 70 70 70 70 68 64 64 64 68 70 70 
18 90 90 90 86 84 80 80 80 80 88 88 88 
19 70 70 70 70 70 70 70 70 70 72 70 70 
20 70 70 70 70 70 70 70 70 70 72 70 70 
21 70 70 70 70 70 70 70 70 70 70 70 70 
22 70 70 70 70 70 70 70 70 70 72 70 70 
23 70 70 70 70 70 70 70 70 70 70 72 74 
24 70 70 70 70 70 70 70 70 70 70 70 70 
25 80 80 80 80 80 78 78 78 78 76 78 80 
26 70 70 70 70 70 70 70 70 70 72 70 74 
27 80 80 80 80 80 74 72 70 70 76 84 80 
28 80 80 80 80 80 80 78 74 70 78 80 80 
29 70 70 70 70 70 70 70 70 68 72 72 70 
30 80 80 80 80 80 80 78 78 78 80 80 80 
 
 
GROUP B - BUPIVACAINE  SPO2% CHART 
S.No 0 Mins 
2 
Mins 
5 
Mins 
10 
Mins 
15 
Mins 
30 
Mins 
1hr 2hrs 3hrs 6hr 12hr 24hr 
1 100 100 100 100 100 100 100 100 99 99 100 100 
2 100 100 100 100 100 99 99 99 99 99 99 100 
3 100 100 100 100 100 100 99 99 99 99 99 100 
4 100 100 100 100 100 100 100 100 100 100 100 100 
5 100 100 99 98 98 98 98 98 98 98 98 98 
6 99 99 99 99 99 99 99 99 99 99 99 99 
7 100 100 100 99 99 99 99 99 99 99 99 99 
8 99 99 99 99 99 99 99 99 99 99 99 99 
9 100 100 100 99 99 99 99 99 99 99 99 99 
10 100 100 100 100 100 99 99 98 99 99 98 100 
11 100 100 100 99 99 99 99 99 99 99 99 99 
12 100 100 100 99 99 99 99 99 99 99 99 99 
13 100 100 100 99 99 99 99 99 99 99 99 99 
14 100 100 100 100 100 99 99 99 99 99 99 100 
15 100 100 100 99 99 99 99 99 99 99 99 99 
16 100 100 100 99 99 99 99 99 99 99 99 99 
17 100 100 100 100 99 99 99 99 99 99 99 99 
18 99 99 99 99 99 98 98 98 99 99 98 99 
19 100 100 100 99 99 99 99 99 99 99 99 99 
20 100 100 100 99 99 99 98 98 98 98 98 99 
21 100 100 100 99 99 99 98 98 98 98 98 99 
22 99 99 99 99 98 98 98 98 99 99 98 98 
23 98 98 98 99 99 99 99 99 99 99 99 99 
24 100 100 100 100 100 100 99 99 99 99 99 100 
25 100 100 100 100 100 100 100 100 100 100 100 100 
26 100 100 100 100 100 100 99 99 99 99 99 100 
27 99 99 99 99 99 99 99 100 100 100 100 99 
28 100 100 100 100 100 100 100 100 100 100 100 100 
29 100 100 100 100 100 100 100 100 100 100 100 100 
30 99 99 99 99 99 100 100 100 100 100 100 99 
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1 28 M 62 I #Lt Thumb ppx-ORIF 12 5 5 4.2 5.5 1.5 nil 2 
2 50 F 65 I BB#R F-arm_ORIF 11 7 6.3 5.4 7.3 2 nil 1 
3 34 M 63 I R-F3,Tendon injury_Repair 9 6 5.8 4.6 7 2.5 nil 1 
4 40 M 66 I Lt ElbowTumor_EX,BIOPSY 13 5 6 4.2 7.1 1 nil 1 
5 28 M 64 I Cut Injury  R-wrist_Repair 9 4 5.7 4.7 6.5 2 nil 1 
6 32 M 66 I Degloving Injury R Hand_W.DEB 9 6 6.2 5.5 7 1.5 nil 1 
7 30 F 60 I BB#L F-arm_ORIF 11 7 6 5.4 6.5 2 nil 2 
8 36 F 61 I BB#R F-arm_ORIF 10 8 7.1 3.9 22 2 nil 0 
9 28 M 67 I FT InjuryR hand_Repair 6 4 6.8 5.2 7.5 2 nil 1 
10 52 M 68 II Galazzi#Lt hand_ORIF 12 6 7.6 3.8 6.5 2 nil 1 
11 36 F 66 I #SOH R _ORIF 12 5 6 4.8 7 2.5 nil 1 
12 28 M 69 I Cut Injury  R-Hand_Repair 11 5 5.1 4.2 6.1 1.5 nil 1 
13 36 M 68 I #Distal ULNA_ORIF 10 7 5 5.5 6 2 nil 1 
14 32 M 72 I Trumatic Ampu RF_RevisionAmpu 10 7 5.5 5.2 6.2 1.5 nil 1 
15 34 M 76 I #SOH Lt_ORIF 11 7 6.7 4.5 7 2.5 nil 1 
16 26 M 65 I Galazzi#Rt hand_ORIF 9 6 6.1 5.4 6.2 2 nil 1 
17 60 M 70 II #SOH Lt_ORIF 6 5 5.5 4.8 7 2 nil 1 
18 42 M 78 I BB#L F-arm_ORIF 13 6 5 4.1 5 1.5 nil 2 
19 55 M 65 II #Radialhead Lt -Exision 9 6 6.2 3.4 6.5 1.5 nil 1 
20 25 M 73 I Gangrene Lt hand_Amputation 13 6 6 4.5 6.3 1.5 nil 1 
21 55 M 68 II #lt 2,3.ppx Lt hand_K-Wirefixation 9 7 6 4.9 6.5 1 nil 1 
22 38 M 75 I R-F3,#_K-Wire Fixation 10 5 5.2 5 6 1.5 nil 2 
23 37 M 77 I Rawarea Rt Hand_SSG 10 4 4.9 3.9 5.4 1.5 nil 1 
24 19 M 63 I PBC Rhand-Release@SSG 10 6 6.1 5.6 7.6 2 nil 1 
25 27 M 65 I PBC Lhand-Release@SSG 11 5 5 3.1 6.3 2 nil 1 
26 55 F 62 II Rawarea Rt F arm_SSG 12 6 6.2 4.8 7.3 1.5 nil 1 
27 35 M 68 I Rawarea Rt Hand_SSG 8 7 6.1 5.2 6.8 1.5 nil 1 
28 20 M 64 I Raw area Lt palm_SSG 8 7 6.1 5 7.5 1.5 nil 1 
29 52 M 61 I Lt BEStump_closure 10 5 6.1 4.5 6.1 1.5 nil 1 
30 22 F 60 I BB#Lt hand_ORIF 8 5 5 4.1 6 2 nil 2 
GROUP BT - BUPIVACAINE AND TRAMADOL PULSE RATE CHART (beats/mins) 
S.No 
0 
Mins 
2 
Mins 
5 
Mins 
10 
Mins 
15 
Mins 
30 
Mins 
1hr 2hrs 3hrs 6hrs 12hrs 24hrs 
1 76 75 76 77 75 78 76 79 80 72 79 80 
2 82 81 80 84 81 83 90 84 86 80 86 81 
3 90 90 82 80 84 84 83 82 84 81 83 83 
4 110 106 102 100 98 98 96 95 94 98 90 92 
5 82 82 80 80 76 76 75 75 74 80 82 85 
6 88 86 85 85 84 84 82 82 82 85 82 88 
7 72 72 70 70 68 68 66 65 65 70 72 65 
8 84 84 80 80 76 75 74 74 72 80 76 80 
9 77 76 75 74 72 72 74 74 68 74 76 74 
10 73 72 70 68 66 68 67 67 66 65 66 70 
11 88 86 85 85 84 84 82 82 82 85 82 80 
12 78 75 74 72 70 70 69 69 68 70 75 76 
13 120 118 115 114 110 110 106 105 100 94 99 100 
14 114 112 110 106 105 104 100 100 98 110 101 98 
15 79 78 75 74 72 74 70 70 70 76 72 73 
16 77 76 75 74 72 76 72 70 70 76 70 75 
17 81 80 78 76 75 77 76 76 76 80 80 82 
18 86 85 84 83 80 82 80 78 78 80 82 82 
19 78 76 75 75 72 76 74 74 74 74 72 76 
20 72 72 70 68 68 69 70 70 68 72 78 68 
21 74 74 72 70 70 70 68 68 68 75 66 62 
22 76 75 74 72 70 70 66 66 66 70 78 76 
23 77 76 75 74 72 74 72 70 70 78 72 80 
24 71 70 68 68 66 66 66 66 66 70 70 69 
25 79 78 76 75 74 74 72 72 72 74 79 70 
26 69 68 66 65 64 66 64 62 62 72 78 90 
27 93 92 90 90 88 88 85 85 84 80 88 88 
28 89 88 86 85 84 86 84 84 84 82 90 85 
29 92 90 88 86 85 86 84 84 82 81 85 91 
30 70 70 68 67 66 67 66 66 65 77 69 69 
 
GROUP BT BUPIVACAINE  AND TRAMADOL   
SYSTOLIC BLOOD PRESSURES CHART (mmHg) 
S.No 
0 
Mins 
2 
Mins 
5 
Mins 
10 
Mins 
15 
Mins 
30 
Mins 
1hr 2hrs 3hrs 6hrs 12hrs 24hrs 
1 130 130 128 126 122 126 130 130 132 130 130 130 
2 120 120 118 116 116 120 122 124 126 120 120 120 
3 120 120 118 116 120 120 120 120 122 120 120 120 
4 126 126 126 126 126 126 130 130 132 130 130 130 
5 130 130 130 128 130 130 130 132 132 130 130 130 
6 140 140 140 138 140 140 140 140 140 136 134 130 
7 110 110 110 110 110 106 110 114 116 110 110 110 
8 120 120 120 118 120 120 120 122 122 120 120 120 
9 110 110 110 110 110 110 110 112 114 110 110 110 
10 130 130 130 128 130 130 130 128 128 130 120 120 
11 120 120 120 118 120 118 122 126 126 120 120 120 
12 130 130 130 128 130 128 130 132 132 130 130 130 
13 120 120 120 118 118 120 120 124 124 120 118 118 
14 130 130 130 128 128 130 130 132 132 130 128 128 
15 120 120 120 118 118 120 120 124 126 118 118 118 
16 110 110 110 110 110 110 114 122 124 110 110 110 
17 140 140 140 138 138 140 140 140 140 130 130 130 
18 130 130 130 130 128 130 130 130 130 124 124 124 
19 120 120 120 120 122 120 120 124 124 120 120 120 
20 130 130 130 128 128 128 128 126 126 124 124 124 
21 140 140 140 138 138 140 140 140 140 130 130 130 
22 120 120 120 120 120 116 116 122 122 120 120 120 
23 120 120 120 118 118 116 118 120 120 120 120 120 
24 110 110 110 108 108 106 108 110 112 110 110 110 
25 130 130 130 128 128 124 124 126 128 126 126 120 
26 120 120 120 118 118 116 116 120 120 120 120 120 
27 120 120 120 120 120 118 116 116 116 120 120 120 
28 120 120 120 118 118 116 116 120 120 120 120 120 
29 140 140 138 138 136 136 134 140 140 130 130 130 
30 120 120 120 118 118 114 116 120 120 114 114 120 
 
GROUP BT BUPIVACAINE AND TRAMADOL  
DIASTOLIC BLOOD PRESSURES  CHART (mmHg)  
S.No 
0 
Mins 
2 
Mins 
5 
Mins 
10 
Mins 
15 
Mins 
30 
Mins 
1hr 2hrs 3hrs 6hrs 12hrs 24hrs 
1 80 80 80 78 78 76 76 76 76 76 80 76 
2 80 80 78 78 76 76 74 74 72 74 80 80 
3 70 70 70 70 68 64 64 64 64 70 70 70 
4 78 78 78 78 76 70 70 70 70 70 70 70 
5 80 80 80 80 76 76 74 74 74 80 80 80 
6 80 80 80 80 80 76 76 74 74 80 80 80 
7 70 70 70 70 70 70 68 68 68 70 70 74 
8 70 70 70 70 68 68 68 68 66 70 70 74 
9 80 80 80 80 78 78 76 76 74 80 80 80 
10 80 80 80 80 78 78 76 76 76 80 80 80 
11 70 70 70 70 70 70 70 70 70 70 70 72 
12 80 80 80 80 78 78 78 76 74 80 80 80 
13 80 80 80 80 78 76 76 74 74 80 80 82 
14 70 70 70 70 68 66 66 66 66 70 70 70 
15 70 70 70 70 68 68 68 66 64 70 70 70 
16 70 70 70 70 68 68 66 66 64 70 70 72 
17 80 80 80 80 78 78 78 78 78 78 78 80 
18 80 80 80 80 78 78 76 76 74 80 80 80 
19 80 80 80 80 80 78 78 76 76 80 80 80 
20 70 70 70 70 68 68 68 66 66 70 70 72 
21 80 80 80 80 80 78 78 76 76 80 80 80 
22 80 80 80 80 80 78 76 76 76 80 80 80 
23 70 70 70 70 68 68 68 68 68 70 70 72 
24 70 70 70 70 68 68 66 64 64 70 70 72 
25 80 80 80 80 78 78 76 74 74 80 80 84 
26 70 70 70 70 68 68 66 66 64 70 70 70 
27 70 70 70 70 70 70 70 70 70 70 70 70 
28 70 70 70 70 68 68 68 66 66 70 70 70 
29 80 80 80 78 78 78 76 76 76 80 80 80 
30 80 80 80 78 78 76 76 76 76 80 80 80 
 
 
 
GROUP BT - BUPIVACAINE AND TRAMADOL SPO2% CHART 
S.No 
0 
Mins 
2 
Mins 
5 
Mins 
10 
Mins 
15 
Mins 
30 
Mins 
1hr 2hrs 3hrs 6hrs 12hrs 24hrs 
1 100 100 99 100 100 100 100 100 100 100 100 100 
2 99 99 99 100 100 100 100 99 99 99 99 100 
3 100 100 100 100 100 100 100 100 100 100 100 100 
4 100 100 100 99 99 100 100 98 99 99 98 100 
5 100 100 100 100 100 98 99 99 99 99 99 98 
6 99 99 99 100 100 99 99 99 99 99 99 99 
7 100 100 100 100 100 99 99 99 99 99 99 99 
8 100 100 100 100 99 99 99 99 99 99 99 99 
9 100 100 100 100 99 98 98 98 98 98 98 98 
10 99 99 99 99 98 98 98 98 99 99 98 98 
11 100 100 100 100 99 99 98 98 99 99 98 99 
12 100 100 100 99 99 99 99 99 99 99 99 99 
13 100 100 100 100 98 98 98 99 99 99 99 98 
14 100 100 100 100 99 99 99 98 99 99 98 99 
15 99 99 100 99 99 99 99 99 99 99 99 99 
16 100 100 100 100 99 98 98 99 99 99 99 98 
17 99 99 99 99 98 98 98 98 99 99 98 98 
18 100 100 100 100 99 99 99 99 98 98 99 99 
19 98 98 98 98 99 99 99 99 99 99 99 99 
20 100 100 100 99 99 99 99 98 99 99 98 99 
21 99 99 99 99 99 99 99 99 99 99 99 99 
22 100 100 100 100 99 99 99 98 99 99 98 99 
23 100 100 100 100 99 99 99 99 99 99 99 99 
24 100 100 100 99 99 99 99 98 98 98 98 99 
25 100 100 100 99 99 99 99 98 99 99 98 99 
26 99 99 99 98 98 99 99 99 99 99 99 99 
27 100 100 100 99 99 98 98 98 99 99 98 98 
28 100 100 100 99 99 98 98 98 98 98 98 98 
29 99 99 99 98 98 98 98 99 99 99 99 98 
30 100 100 100 99 99 99 99 98 99 99 98 99 
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